Hyperlipidemia

On this page

Quick Reference

RxDrug of choiceHigh-intensity statin (atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily) for ASCVD and high-risk primary prevention.

AltAlternativesEzetimibe 10 mg daily, PCSK9 inhibitors (evolocumab 140 mg SC q2w or 420 mg monthly; inclisiran 300 mg SC at day 1, month 3, then q6mo), bempedoic acid 180 mg daily (statin intolerance), fenofibrate 160 mg daily for hypertriglyceridemia.

⊘AvoidGemfibrozil with statins (rhabdomyolysis risk); policosanol, guggulipid, and red yeast rice (no efficacy); niacin extended-release (poor tolerability, no cardiovascular benefit when added to statin).

DxTest of choiceFasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides); Lp(a) measured once; genetic testing for LDLR, APOB, PCSK9 if FH suspected (LDL-C ≥190 mg/dL).

ScKey scoreDutch Lipid Clinic Network criteria for FH (score >8 = definite FH); Pooled Cohort Equations (ACC/AHA) for 10-year ASCVD risk classification.

→When to referSuspected or confirmed FH (especially children, young adults with LDL-C ≥190 mg/dL), severe hypertriglyceridemia (≥1000 mg/dL) refractory to fibrate, statin intolerance requiring PCSK9i or bempedoic acid, need for lipoprotein apheresis.

Start high-intensity statin in all ASCVD patients and high-risk primary prevention; add ezetimibe then PCSK9i if not at goal; treat triglycerides ≥500 mg/dL with fibrate to prevent pancreatitis; screen family members when FH is confirmed.

Hyperlipidemia, typically defined as elevated LDL-C and/or triglycerides, is the most modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Affecting over 70% of adults with hypertension, it is causally linked to myocardial infarction, stroke, and peripheral artery disease. The cornerstone of management is high-intensity statin therapy, with addition of ezetimibe, PCSK9 inhibitors, or bempedoic acid as needed to achieve guideline targets (LDL-C <55 mg/dL for very high risk, <70 mg/dL for high risk, <100 mg/dL for moderate risk). Severe hypertriglyceridemia (≥500 mg/dL) requires fibrates or icosapent ethyl to prevent pancreatitis. Early detection, risk stratification with tools like the Pooled Cohort Equations, and cascade screening for familial hypercholesterolemia are essential to reduce the global burden of ASCVD.

Overview and Recommendations

Background

•Hyperlipidemia, elevation of LDL-C, triglycerides, or both, affects approximately 73% of US adults with hypertension and accounts for roughly half the population-attributable risk of myocardial infarction. Lifetime risk of cardiovascular disease at age 50 with all major risk factors present is 38% in men and 24% in women, underscoring the profound prognostic stakes.
•The four pillars of guideline-directed medical therapy, high-intensity , , , and , have replaced the older statin-alone paradigm following landmark trials such as IMPROVE-IT (ezetimibe add-on), FOURIER (PCSK9i), and CLEAR-Outcomes (bempedoic acid). Combined LDL-C reduction can exceed 80% with statin plus a PCSK9 inhibitor.
•Subendothelial retention of apolipoprotein B-containing lipoproteins (chiefly LDL and VLDL remnants) is the initiating event in atherogenesis. Oxidative modification of retained LDL triggers endothelial activation, monocyte recruitment, and foam-cell formation, the core pathophysiological cascade that progresses to plaque formation and rupture.
•Primary (genetic) hyperlipidemia includes familial hypercholesterolemia (FH; prevalence 1:250 for heterozygotes), familial combined hyperlipidemia (1:100), and severe hypertriglyceridemia syndromes. Secondary causes, diabetes, hypothyroidism, nephrotic syndrome, cholestasis, and medications (thiazides, retinoids, protease inhibitors), must be excluded before labeling a patient with a primary disorder.
•Untreated hyperlipidemia accelerates atherosclerotic progression: premature ASCVD (MI or stroke before age 55 in men, 60 in women) is a hallmark of FH. Primary prevention with statins reduces all-cause mortality by 14% (RR 0.86) and major cardiovascular events by approximately 30%, with consistent benefit across age and sex subgroups.

Evaluation

•Suspect hyperlipidemia in any patient with exertional dyspnea, unexplained fatigue, or a family history of premature ASCVD, especially when combined with stigmata such as xanthomas or xanthelasma on physical exam.
•Ask about prior lipid values, personal history of coronary artery disease, stroke, or peripheral artery disease, and any history of acute pancreatitis (marker of severe hypertriglyceridemia). Thoroughly review medications: thiazides, non-selective beta-blockers, retinoids, anabolic steroids, and protease inhibitors can all elevate lipids.
•Examine for tendon xanthomas, palpate the Achilles tendon while the foot is dorsiflexed; nodular thickening is pathognomonic for (FH). Also check for xanthelasma palpebrarum, arcus corneae before age 45, and eruptive xanthomas (yellow papules on extensor surfaces) that indicate severe hypertriglyceridemia.
•Order a fasting lipid panel as the gold-standard initial test: measure total cholesterol, LDL-C, HDL-C, and triglycerides. A non-fasting panel is acceptable for initial screening; if total cholesterol ≥200 mg/dL or HDL-C <40 mg/dL, repeat with fasting to confirm.
•Assess for secondary causes of hyperlipidemia with laboratory studies: TSH (hypothyroidism), HbA1c or fasting glucose (diabetes), urine protein or albumin-creatinine ratio (nephrotic syndrome), and hepatic transaminases (cholestasis, non-alcoholic fatty liver disease).
•Calculate 10-year ASCVD risk using the (ACC/AHA) or SCORE (ESC) for all adults aged 40-75 years without established ASCVD. Categories: low (<5%), borderline (5-7.5%), intermediate (7.5-20%), and high (≥20%).
•When LDL-C is ≥190 mg/dL, apply the (DLCN) criteria: assign points based on LDL-C level, family history, personal ASCVD, and physical signs. A score >8 defines definite FH, while 6-8 indicates probable FH. Genetic testing for LDLR, APOB, and PCSK9 mutations is recommended for patients with DLCN score ≥6.
•Measure [Lp(a)] once in adults; a level ≥50 mg/dL (or ≥125 nmol/L) is an independent risk-enhancing factor that warrants more intensive lipid lowering even if LDL-C appears well controlled.
•In patients with triglycerides ≥500 mg/dL, rule out familial chylomicronemia syndrome (genetic testing for LPL, APOC2, APOA5) and consider urgent therapy to prevent pancreatitis. Also check for contributory factors such as uncontrolled diabetes, excess alcohol intake, and estrogen therapy.
•For intermediate-risk patients (7.5-20% 10-year risk), refine risk assessment with coronary artery calcium scoring or high-sensitivity CRP (hsCRP ≥2 mg/L indicates residual inflammatory risk). A CAC score of zero can reclassify many to low risk, potentially deferring statin therapy.

Management

•Initiate high-intensity statin therapy immediately for all patients with established ASCVD: 40-80 mg daily or 20-40 mg daily, regardless of baseline LDL-C level. For primary prevention with LDL-C ≥190 mg/dL or 10-year risk ≥20%, start a high-intensity statin as first-line.
•Begin statin therapy at moderate intensity (atorvastatin 10-20 mg or rosuvastatin 5-10 mg) for primary prevention patients with intermediate risk (7.5-20%). Titrate every 4-12 weeks to achieve ≥50% LDL-C reduction.
•Add 10 mg daily if LDL-C remains ≥70 mg/dL (or ≥55 mg/dL in very high risk, defined as ASCVD with major risk factors or recurrent events) after 12 weeks of maximally tolerated statin. Ezetimibe provides an additional ~15-20% LDL-C reduction.
•For very high risk patients not at goal on statin plus ezetimibe, advance to a : 140 mg subcutaneously every 2 weeks or 420 mg monthly; or 300 mg subcutaneously at day 1, month 3, then every 6 months. These agents reduce LDL-C by approximately 50-60% on top of background therapy.
•For patients with statin intolerance (confirmed myalgia or CK elevation not due to other causes), consider 180 mg daily. In CLEAR-Outcomes, it reduced LDL-C by 21% and hsCRP by 22% with no excess muscle symptoms, even in patients aged ≥75 years.
•For severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL), start 160 mg daily to reduce pancreatitis risk. Add 2 g twice daily if triglycerides remain elevated or for residual cardiovascular risk. Do not use gemfibrozil with statins due to rhabdomyolysis risk; fenofibrate is the preferred fibrate for combination therapy.
•Monitor hepatic transaminases and creatine kinase at baseline and 4-12 weeks after starting or dose-escalating any statin. Do not discontinue statins for mild, non-progressive myalgias without a dechallenge-rechallenge trial; the absolute excess risk of myalgia in double-blind trials is only 2.7 per 1000 patients.
•Avoid ineffective or harmful therapies: policosanol, guggulipid, and red yeast rice have no proven LDL-C reduction beyond placebo. Niacin extended-release is no longer recommended due to lack of cardiovascular benefit and poor tolerability (25% discontinuation from flushing).
•Refer to cardiology or a lipid specialist when FH is suspected (especially in young adults or children with LDL-C ≥190 mg/dL), triglycerides remain ≥1000 mg/dL despite fibrate therapy, or when statin intolerance requires advanced therapies like PCSK9 inhibitors or bempedoic acid.
•For homozygous FH (HoFH) with LDL-C >100 mg/dL despite maximal pharmacotherapy, consider every 1-2 weeks; it acutely reduces LDL-C by 60-70% and, in registry data, reduces cardiovascular events by approximately 70%. Ensure cascade screening of all first-degree relatives of FH probands.

Board Review — High Yield

•Tendon xanthomas, Pathognomonic for familial hypercholesterolemia (FH); palpate Achilles tendon with foot dorsiflexed; indicates need for genetic testing.
•Dutch Lipid Clinic Network score, Definite FH: score >8 (uses LDL-C, family history, personal ASCVD, physical findings); >6 points suggests probable FH.
•PCSK9 inhibitors, Evolocumab 140 mg SC q2w or 420 mg monthly; achieves ~60% LDL-C reduction; inclisiran 300 mg SC at day 1, month 3, then q6mo offers siRNA-based sustained reduction.
•Bempedoic acid, Alternative for statin intolerance; reduces LDL-C by ~21% and hsCRP by ~22% without muscle toxicity (CLEAR-Outcomes).
•Lp(a), Independent risk factor measured once in adults; ≥50 mg/dL (or ≥125 nmol/L) intensifies risk; no specific approved therapy yet, but it justifies more aggressive LDL-C lowering.
•Severe hypertriglyceridemia, Triglycerides ≥500 mg/dL → risk of acute pancreatitis; first-line fibrate (fenofibrate 160 mg daily) plus lifestyle modification.
•ASCVD risk scores, Pooled Cohort Equations for 10-year risk: high (≥20%), intermediate (7.5-20%), borderline (5-7.5%), low (<5%). Consider CAC scoring for intermediate risk.
•Lipoprotein apheresis, For homozygous FH with LDL-C >100 mg/dL despite maximal drug therapy; reduces LDL-C by 60-70% per session every 1-2 weeks.
•Statins in primary prevention, JUPITER: rosuvastatin 20 mg reduced major CV events by 44% (NNT ~95) in healthy individuals with hsCRP ≥2 and LDL-C <130 mg/dL.
•Cascade screening, All first-degree relatives of FH probands should be screened with lipid panel and genetic testing if possible; identifies at least one affected relative in ~50% of families.

Deep Dive — Evidence Details

Definition, Classification and Nomenclature

▸Hyperlipidemia is defined by elevated LDL-C, triglycerides, or both and is a major modifiable ASCVD risk factor.
▸Classification by etiology (primary vs. secondary) and phenotype (Fredrickson types) directs management strategy.
▸Severe hypertriglyceridemia >500 mg/dL increases pancreatitis risk and requires distinct treatment.

Hyperlipidemia is an elevation of one or more plasma lipids, low-density lipoprotein cholesterol (LDL-C), triglycerides, or total cholesterol, that constitutes a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). The term is used interchangeably with dyslipidemia (which also includes low high-density lipoprotein cholesterol [HDL-C]) and with hyperlipoproteinemia.

Synonyms and Abbreviations

Hyperlipidemia (HLD)
Dyslipidemia
Hyperlipoproteinemia
(elevated LDL-C or total cholesterol)
(elevated triglycerides)

Classification Axes

Classification drives and follows two complementary systems:

1. Etiologic (Primary vs. Secondary)

Primary (genetic) hyperlipidemia: monogenic disorders such as familial hypercholesterolemia (FH), characterized by lifelong LDL-C ≥190 mg/dL in adults, tendon xanthomas, and premature ASCVD ^[1]^A1c, and polygenic susceptibility.
Secondary (acquired) hyperlipidemia: results from conditions including type 2 diabetes, hypothyroidism, nephrotic syndrome, cholestasis, and medications (e.g., corticosteroids, thiazides).

2. Phenotypic (Lipid Profile Pattern) The Fredrickson classification organizes hyperlipoproteinemias by electrophoretic pattern and the predominant lipoprotein elevated:

Phenotype	Elevated Lipoprotein	Key Lipid Abnormality	Clinical Association
Type I	Chylomicrons	Severe triglycerides (>>1000 mg/dL)	Pancreatitis risk
Type IIa	LDL	High LDL-C	FH, premature ASCVD
Type IIb	LDL + VLDL	High LDL-C and triglycerides	Combined hyperlipidemia
Type III	IDL (β-VLDL)	High cholesterol and triglycerides (equal)	Dysbetalipoproteinemia
Type IV	VLDL	High triglycerides	Metabolic syndrome
Type V	Chylomicrons + VLDL	Severe triglycerides	Pancreatitis risk

Key Terms Used Throughout This Article

LDL-C: low-density lipoprotein cholesterol, the primary atherogenic particle.
HDL-C: high-density lipoprotein cholesterol; higher levels are inversely associated with ASCVD risk.
Non-HDL-C: total cholesterol minus HDL-C, capturing all atherogenic apolipoprotein B-containing lipoproteins.
Lipoprotein(a) [Lp(a)]: an LDL-like particle with prothrombotic and proinflammatory properties.
Familial hypercholesterolemia (FH): an autosomal dominant disorder causing markedly elevated LDL-C from birth; prevalence is ~1 in 250 for heterozygous and ~1 in 300,000 for homozygous FH.

Clinical Significance

Hyperlipidemia is causally linked to atherosclerosis progression and ASCVD events. In the MESA cohort, individuals with combined hyperlipidemia or simple hypercholesterolemia had significantly increased common carotid intima-media thickness (by 0.048 mm each) and a 22% higher risk of prevalent coronary artery calcium compared with normolipemic participants ^[5]^B2c. Severe hypertriglyceridemia (triglycerides >500 mg/dL) confers risk of acute pancreatitis ^[29]^C4. Globally, elevated atherogenic lipids are common: in a study of 461 million lipid results from 17 countries, nearly 10% of women and 9% of men in North Macedonia had LDL-C >4.91 mmol/L (190 mg/dL) ^[17]^B2c. These epidemiologic patterns set the stage for the risk factor discussion that follows.

Pearl: When classifying a patient's hyperlipidemia, first distinguish primary (genetic) from secondary causes, treating the underlying condition (e.g., hypothyroidism) often normalizes lipids without pharmacotherapy.

Epidemiology and Risk Factors

▸Hyperlipidemia prevalence varies widely by geography, age, sex, and race, with the highest LDL-C levels (>190 mg/dL) seen in North Macedonia.
▸Obesity is the most potent modifiable risk factor, with extreme obesity tripling all-cause mortality partly through lipid-mediated pathways.
▸Control rates for hyperlipidemia among high-risk populations have plateaued at approximately 32% over the past decade, highlighting a major implementation gap.

HY High Yield: Despite declining prevalence in young US adults, hyperlipidemia control remains suboptimal (<33%) in those with coexisting hypertension, representing a key missed opportunity for cardiovascular prevention.

Building on the classification framework, the global burden of hyperlipidemia is substantial and varies widely across populations. Mean total cholesterol levels range from 4.58 mmol/L (177.1 mg/dL) in the Republic of Korea to 5.40 mmol/L (208.8 mg/dL) in Austria, with the highest proportions of LDL-C >4.91 mmol/L (>190 mg/dL) observed in North Macedonia (9.9% of women, 8.7% of men) ^[17]^B2c. In the United States, hyperlipidemia affects 73.1% of adults with (2021-2023), though control rates for concurrent hypertension and hyperlipidemia remain low at 32.3% (95% CI 29.5%-35.2%) ^[54]^B2c. Among young adults aged 20-44 years, hyperlipidemia prevalence declined from 40.5% in 2009-2010 to 36.1% in 2017-2020, while obesity rose from 32.7% to 40.9% over the same period ^[72]^B2c. Rural-urban disparities exist: rural US adults have a higher age-standardized hyperlipidemia prevalence than urban counterparts (29.3% vs. 26.7%; rate ratio 1.10, 95% CI 1.03-1.18) ^[64]^B2c.

Demographic and Geographic Variation

Lipid profiles peak at 50-59 years in women and 40-49 years in men, with sex differences narrowing after ^[17]^B2c. Black men have the highest prevalence of intracranial atherosclerotic plaque (50.9%), and midlife hyperlipidemia is associated with an 18% higher prevalence of late-life intracranial atherosclerosis (prevalence ratio 1.18; 95% CI 0.98-1.42) ^[24]^B2c. Special populations carry a disproportionate burden: among people living with HIV, the pooled prevalence of high cholesterol is 47.3% (95% CI 36.3%-58.4%) ^[58]^A1a; adults with lower-complexity congenital heart disease have a 41% prevalence of hyperlipidemia ^[51]^B2b.

Temporal Trends

From 1996 to 2016, US health spending on hyperlipidemia treatment rose by $18 billion, driven by service price and intensity ^[50]^B2c. However, among US adults with hypertension, the proportion achieving concurrent control of hypertension and hyperlipidemia plateaued at 32.3% after 2007, with no improvement over the past decade ^[54]^B2c.

Risk Factor Profile

Obesity is a strong modifiable driver: extreme obesity (BMI ≥40) confers an all-cause mortality rate of 116.85 per 10,000 person-years, with much of the excess risk mediated through hyperlipidemia, diabetes, and hypertension ^[75]^B2b. Metabolic abnormalities cluster: among adults with hypertension, the prevalence of concurrent diabetes and hyperlipidemia nearly doubled from 12.5% (1999-2000) to 21.3% (2021-2023) ^[54]^B2c. Non-modifiable factors include age, male sex, family history, and genetic conditions such as familial ^[1]^A1c. Childhood adverse experiences, such as parental incarceration, are associated with a 60% higher adjusted odds of elevated high-sensitivity C-reactive protein (hsCRP >3 mg/L) in adulthood, though not independently with hyperlipidemia diagnosis ^[66]^B2b. Premature menopause (before age 40) is linked to increased incident hyperlipidemia ^[71]^B2b.

Risk Factors for Hyperlipidemia

Factor	Odds Ratio / Rate Ratio (95% CI)	Evidence Source
Rural vs. urban residence (US)	RR 1.10 (1.03-1.18)	^[64]^B2c
Midlife hyperlipidemia → intracranial atherosclerosis	PR 1.18 (0.98-1.42)	^[24]^B2c
Extreme obesity (BMI ≥40) vs. normal weight	All-cause mortality 116.85 vs. 68.39 per 10,000 PY	^[75]^B2b
Childhood parental incarceration → elevated hsCRP	OR 1.60 (1.03-2.48)	^[66]^B2b
HIV infection → high cholesterol prevalence	Pooled prevalence 47.3%	^[58]^A1a

Pearl: The prevalence of hyperlipidemia remains high (73%) among US adults with hypertension, yet fewer than one in three achieve concurrent control, an opportunity to close a persistent treatment gap ^[54]^B2c.

Prevalence and Risk of Hyperlipidemia Across Selected Populations

Population	Prevalence / Effect Estimate (95% CI)	Source
US adults with hypertension (2021-2023)	73.1% (70.6%-75.4%)	^[54]^B2c
US young adults 20-44 yr (2017-2020)	36.1% (33.5%-38.7%)	^[72]^B2c
Rural US adults vs. urban	RR 1.10 (1.03-1.18)	^[64]^B2c
PLHIV (pooled)	47.3% (36.3%-58.4%)	^[58]^A1a
Lower-complexity ACHD	41%	^[51]^B2b
North Macedonia (LDL-C >4.91 mmol/L)	9.9% women, 8.7% men	^[17]^B2c

Pathophysiology and Mechanism

▸Subendothelial retention of apoB-containing lipoproteins is the initiating event in atherogenesis; oxidative modification and SREBP2-mediated NLRP3 inflammasome activation in endothelium are critical early steps [90].
▸Hyperlipidemia drives neutrophilia and monocytosis, accelerating early plaque formation through CCR-dependent recruitment [85].
▸Low endothelial shear stress synergizes with expansive remodeling to determine focal plaque progression and vulnerability [87].

The pathogenetic sequence begins with the subendothelial retention of apolipoprotein B (apoB)-containing lipoproteins, primarily (LDL) and very-low-density lipoprotein remnants. This retention is the sine qua non of atherogenesis and is driven by elevated plasma concentrations coupled with increased arterial wall permeability at sites of disturbed flow.

Lipoprotein Retention and Oxidative Modification

Once retained in the intima, LDL particles undergo oxidative modification by enzymes such as 15-lipoxygenase and myeloperoxidase, generating oxidized phospholipids that trigger endothelial activation. Oscillatory shear stress at branch points activates sterol regulatory element-binding protein 2 (SREBP2) in endothelial cells, which transactivates NADPH oxidase 2 and the NLRP3 inflammasome, creating a proinflammatory milieu that synergizes with hyperlipidemia to determine the topographical distribution of atherosclerotic lesions ^[90]^D5. This mechanism links hemodynamic forces directly to innate immune activation.

Endothelial Activation and Leukocyte Recruitment

Activated endothelium upregulates adhesion molecules (VCAM-1, ICAM-1) and chemokines (MCP-1, CXCL1), promoting monocyte and neutrophil recruitment. Hyperlipidemia itself induces neutrophilia through enhanced granulopoiesis and mobilization from the bone marrow; the degree of neutrophilia correlates positively with early atherosclerotic lesion formation ^[85]^D5. Neutrophils infiltrate arteries primarily during early atherogenesis via CCR1, CCR2, CCR5, and CXCR2, contrasting with venous recruitment that requires only CCR2 and CXCR2 ^[85]^D5. Monocytes, particularly the inflammatory CD14+CD16+ subset in humans, adhere to activated endothelium, migrate into the intima, and differentiate into macrophages ^[81]^D5.

Foam Cell Formation and Plaque Progression

Macrophages scavenge oxidized LDL through scavenger receptors (SR-A, CD36), leading to uncontrolled lipid accumulation and foam cell formation, the hallmark of the fatty streak. Continued lipid loading, combined with inefficient reverse cholesterol transport, drives foam cell apoptosis and the formation of a necrotic core. Concurrently, low endothelial shear stress promotes plaque initiation and progression; excessive expansive remodeling in regions of very low shear stress further exacerbates the hemodynamic insult and is associated with the most marked plaque progression ^[87]^D5. This synergistic relationship between shear stress and remodeling identifies lesions destined to become high-risk plaques.

Role of Inflammation and Plaque Vulnerability

Hyperlipidemia sustains a systemic inflammatory state that amplifies plaque vulnerability. The CXCR7 pathway offers a counterregulatory mechanism: activation of CXCR7 by its ligand CCX771 reduces circulating VLDL levels by promoting cholesterol uptake into white adipose tissue, thereby limiting hyperlipidemia-induced monocytosis ^[86]^D5. Hypercoagulability, paradoxically, may promote plaque stability; thrombin signaling via protease-activated receptor-1 (PAR-1) in monocytes inhibits transendothelial migration in a phospholipase-Cβ-, phosphoinositide 3-kinase-, and nitric oxide-dependent manner, reducing intraplaque macrophage accumulation ^[89]^D5. The balance between these opposing forces, inflammatory recruitment versus thrombin-mediated retention, dictates whether a plaque remains stable or becomes rupture-prone. These mechanisms converge on the clinical phenotype: the transition from a stable to a vulnerable plaque sets the stage for , the central clinical consequence of uncontrolled hyperlipidemia.

Pearl: The initiating event in atherogenesis is the subendothelial retention of apoB-containing lipoproteins; oxidative modification and endothelial activation follow, making LDL lowering the most effective upstream intervention to break the entire cascade.

Key Mediators of Hyperlipidemia-Driven Atherogenesis

Step	Key Mediators	Effect
Lipoprotein retention	ApoB, LDL, VLDL remnants	Accumulation in arterial intima
Oxidative modification	15-lipoxygenase, myeloperoxidase, reactive oxygen species	Generation of oxidized phospholipids, endothelial activation
SREBP2 activation in endothelium	SREBP2, NADPH oxidase 2, NLRP3 inflammasome	Proinflammatory cytokine release (IL-1β, IL-18) ^[90]^D5
Neutrophil mobilization and recruitment	CCR1, CCR2, CCR5, CXCR2, CCL5	Early plaque infiltration, lesion initiation ^[85]^D5
Monocyte recruitment and foam cell formation	MCP-1, VCAM-1, ICAM-1, SR-A, CD36	Lipid-laden macrophages, necrotic core formation ^[81]^D5
Vascular remodeling	Endothelial shear stress, matrix metalloproteinases	Expansive remodeling worsens low shear, drives progression ^[87]^D5

Clinical Presentation

▸Hyperlipidemia is asymptomatic for decades; clinical recognition often occurs with acute coronary syndrome, stroke, or pancreatitis as the first event.
▸Physical stigmata such as tendon xanthomas, arcus corneae before age 45, and eruptive xanthomas are specific to certain phenotypes and should be actively sought.
▸Cumulative exposure to even moderate hyperlipidemia in young adulthood independently predicts future coronary heart disease, supporting early initiation of risk stratification.

HY High Yield: Palpate the Achilles tendon with the foot dorsiflexed to appreciate nodular thickening, this is the most specific finding for FH.

From the preceding pathophysiology, the clinical impact of hyperlipidemia emerges through two distinct pathways: insidious atherosclerosis that accumulates over decades and, at extreme lipid levels, direct tissue deposition of lipids. Most patients remain asymptomatic for years, and the condition is frequently discovered incidentally on routine laboratory screening. However, cumulative exposure to even moderate hyperlipidemia early in adulthood increases coronary heart disease risk in a dose-dependent fashion, with a hazard ratio of 1.39 per decade of exposure after adjustment for other risk factors ^[104]^B2b. At the extremes, patients may present with , stroke, or peripheral artery disease as the first manifestation of underlying atherosclerotic disease.

Presenting Symptoms

The majority of individuals with hyperlipidemia have no attributable symptoms. Symptoms arise when lipid abnormalities have already produced end-organ damage. Acute coronary syndrome is a common sentinel event, particularly in patients with familial (FH) who experience premature myocardial infarction. In patients with severe (typically triglycerides > 1000 mg/dL), acute pancreatitis is the dominant acute presentation, with epigastric pain radiating to the back, nausea, and vomiting. Eruptive xanthomas, yellowish papules with an erythematous halo over the buttocks, elbows, and knees, often accompany triglyceride levels exceeding 2000 mg/dL and regress with lipid lowering. Lipemia retinalis, a creamy appearance of retinal blood vessels, is visible on funduscopy at triglycerides above 3000-4000 mg/dL but does not impair vision. Hepatosplenomegaly may occur from lipid accumulation in reticuloendothelial cells.

Physical Examination Findings

A targeted examination can reveal stigmata of hyperlipidemia that carry diagnostic and prognostic significance:

Xanthelasma palpebrarum: Soft, yellow, cholesterol-rich plaques on the medial canthi; associated with increased cardiovascular risk, though not specific to FH.
Arcus corneae: Gray-white corneal lipid deposition; when present before age 45, it strongly correlates with FH and atherosclerosis.
Tendon xanthomas: Nodular, fibrotic lipid deposits in the Achilles tendon and extensor tendons of the fingers and hands. Palpation of the Achilles tendon while the foot is dorsiflexed reveals thickening; these are pathognomonic for FH. In homozygous FH (HoFH), xanthomas can appear in childhood, and mean baseline LDL-C in affected adolescents is 272 mg/dL ^[3]^A1b.
Eruptive xanthomas: Small, yellow papules on extensor surfaces; indicate severe hypertriglyceridemia (often type I or V hyperlipoproteinemia).
Tuberous and planar xanthomas: Large, firm nodules over elbows and knees; seen in FH and sitosterolemia.
Bruits over the carotid, abdominal aorta, or femoral arteries: suggest advanced atherosclerotic disease.

Examination should also assess for obesity, , and signs of metabolic syndrome (abdominal adiposity, ), as these comorbidities amplify cardiovascular risk.

Phenotypic Variants

Variant	Key Features	Frequency	Distinguishing Exam Findings
Heterozygous FH (HeFH)	LDL-C > 190 mg/dL, premature CAD (before age 55 in men, 60 in women), autosomal dominant	1:250	Tendon xanthomas, arcus corneae, xanthelasma
Homozygous FH (HoFH)	LDL-C > 500 mg/dL, untreated; cutaneous and tendon xanthomas by age 10; aortic valve disease	1:1,000,000	Interdigital web xanthomas, planar xanthomas, severe arcus
Familial combined hyperlipidemia	Elevated LDL-C and/or triglycerides; increased apoB; early CAD; no single genetic defect	1:100	Often no xanthomas; may have xanthelasma; metabolic syndrome features
Severe hypertriglyceridemia (type I, IV, V)	Triglycerides > 1000 mg/dL; acute pancreatitis; eruptive xanthomas	Variable	Eruptive xanthomas, lipemia retinalis, hepatosplenomegaly
Combined hyperlipidemia (MESA)	Associated with greater carotid intima-media thickness (0.048 mm thicker common CIMT) and increased risk of coronary artery calcium (relative risk 1.22) ^[5]^B2c	Common in metabolic syndrome	Abdominal obesity, acanthosis nigricans, hypertension

Red Flags Requiring Urgent Action

Very young age at presentation (LDL-C > 160 mg/dL in children or > 190 mg/dL in adults without secondary causes).
Cutaneous or tendon xanthomas at any age.
Family history of premature atherosclerotic cardiovascular disease (first-degree relative with MI or stroke before age 55 in men, 60 in women).
Acute pancreatitis in the setting of hypertriglyceridemia (triglycerides > 1000 mg/dL).
Symptoms of ischemia (chest pain, dyspnea, claudication) in young adults.

These features prompt immediate further evaluation for FH and early initiation of lipid-lowering therapy.

Atypical Presentations

Hyperlipidemia may first come to clinical attention through unusual manifestations:

Lipemic aqueous humor: Milky-white anterior chamber exudation mimicking uveitis, reported in a young woman with poorly controlled diabetes and severe hypertriglyceridemia; symptoms improved rapidly with control of lipids and corticosteroids ^[29]^C4.
Limbal xanthogranuloma: Bilateral, yellow-white corneoscleral lesions causing visual impairment, histologically showing lipid-laden histiocytes; associated with chronic hyperlipidemia and inflammation ^[110]^C4.
Gallstone disease: Hyperlipidemia increases the risk of progression from asymptomatic to symptomatic (relative risk 1.19, 95% CI 1.07-1.32) ^[30]^A1a.
Peripheral arterial disease: Insulin resistance and inflammation, both common in dyslipidemic states, are independently associated with PAD (odds ratio 2.06 for HOMA-IR quartile 4, and OR 2.2 for CRP > 3 mg/L) ^[105]^C4.
Healed plaques on optical coherence tomography: In ACS patients, healed culprit plaques are more frequent in those with hyperlipidemia (44.4% vs. 33.2%, p = 0.041), suggesting previous silent plaque destabilization ^[106]^B2b.
Intracranial atherosclerosis: Midlife hyperlipidemia is associated with an 18% increased prevalence of intracranial plaques (prevalence ratio 1.18), especially in black men ^[24]^B2c.

Pearl: The presence of tendon xanthomas, particularly in the Achilles tendon, is essentially diagnostic of familial hypercholesterolemia and should trigger cascade screening of first-degree relatives, regardless of the patient's age or symptoms.

Diagnosis and Workup

▸A fasting lipid panel (TC, LDL-C, HDL-C, triglycerides) is the gold-standard diagnostic test; non-fasting panels are acceptable for initial screening.
▸Genetic testing for LDLR, APOB, and PCSK9 mutations should be considered when LDL-C ≥190 mg/dL and DLCN criteria are met.
▸Secondary causes of hyperlipidemia (hypothyroidism, diabetes, nephrotic syndrome, medications) must be excluded before concluding a primary diagnosis.

Dx Diagnostic Essentials: The gold-standard test is a fasting lipid panel measuring total cholesterol, LDL-C, HDL-C, and triglycerides.

HY High Yield: A non-fasting lipid panel is acceptable for primary screening; only request a repeat fasting panel when triglycerides exceed 200 mg/dL or when initiating lipid-lowering therapy.

The clinical presentation of xanthomas, arcus cornealis, or a strong family history of premature cardiovascular disease immediately suggests an underlying hyperlipidemia, but most cases are detected by routine laboratory screening. A fasting lipid panel measuring total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides remains the gold-standard initial test, though non-fasting samples are acceptable for primary screening ^[17]^B2c. The diagnosis is established when lipid levels exceed population-based or guideline-defined thresholds, with the specific cutoffs and patterns guiding further classification.

History and Physical

Directed questioning should elicit prior lipid values, personal or family history of premature atherosclerotic cardiovascular disease (ASCVD), and symptoms of pancreatitis (suggesting severe ). Physical examination may reveal tendinous xanthomas (pathognomonic for familial [FH]), xanthelasma, arcus cornealis (age <45 years), or eruptive xanthomas (severe hypertriglyceridemia). These findings raise the pre-test probability of a heritable dyslipidemia and prompt earlier genetic testing.

Laboratory Studies (Gold-Standard Test)

The diagnostic standard is a lipid panel obtained after a 9-12 hour fast, measuring:

LDL-C (calculated or direct, <100 mg/dL optimal; ≥190 mg/dL suggests FH).
HDL-C (<40 mg/dL in men, <50 mg/dL in women is low).
Triglycerides (fasting <150 mg/dL; >500 mg/dL indicates severe hypertriglyceridemia).
Non-HDL-C (TC minus HDL-C; <130 mg/dL optimal) captures atherogenic particles when triglycerides are elevated.
Lipoprotein(a) [Lp(a)]: measured once in adults; >50 mg/dL (or >125 nmol/L) confers independent risk ^[56]^B2b.
Apolipoprotein B (apoB) provides a direct measure of atherogenic particle number and is useful when triglycerides >300 mg/dL ^[5]^B2c. A non-fasting panel is adequate for initial screening: if TC ≥200 mg/dL or HDL-C <40 mg/dL, repeat with fasting for confirmation. Non-fasting triglycerides >200 mg/dL should prompt a fasting study ^[17]^B2c.

Test	Finding	Diagnostic Implication
LDL-C ≥190 mg/dL	Possible FH	Apply DLCN criteria; consider genetic testing ^[117]^C4
Triglycerides >500 mg/dL	Severe hypertriglyceridemia	Rule out secondary causes; risk of pancreatitis
Lp(a) ≥50 mg/dL	Elevated Lp(a)	Add to risk assessment; no specific therapy yet

Genetic Testing

For patients with LDL-C ≥190 mg/dL and a compatible family history, genetic testing for mutations in LDLR, APOB, and PCSK9 can confirm heterozygous FH. The Dutch Lipid Clinic Network (DLCN) score assigns points based on LDL-C level, family history, personal ASCVD, and physical signs. A score of >8 points defines definite FH. In patients with a clinical diagnosis of familial combined hyperlipidemia, LDLR mutations are found in nearly 20% of cases; TC >335 mg/dL or apoB >185 mg/dL are thresholds that enrich for mutation carriers ^[117]^C4.

Diagnostic Algorithm

Workup proceeds in steps:

Initial screen: Non-fasting or fasting lipid panel in all adults ≥20 years every 4-6 years; earlier in those with ASCVD, diabetes, or strong family history. Children should be screened at age 9-11 ^[1]^A1c.
Abnormal result: Repeat with fasting (if not already) and assess for secondary causes: hypothyroidism (TSH), diabetes (HbA1c), nephrotic syndrome (urine protein), liver disease (LFTs), and medications (thiazides, β-blockers, retinoids, protease inhibitors) ^[91]^B2b.
Elevated LDL-C ≥190 mg/dL: Apply DLCN criteria. If score ≥6, consider genetic testing.
Elevated triglycerides >500 mg/dL: Exclude secondary causes; if persistent and family history positive, refer for specialized genetic testing for familial chylomicronemia syndrome (LPL, APOC2, APOA5, etc.).
Elevated Lp(a): Single measurement; if ≥50 mg/dL, intensify risk factor ^[56]^B2b.

Differential Diagnosis

Secondary hyperlipidemia is common and must be excluded before labeling a patient with primary dyslipidemia. Major causes include:

Hypothyroidism: elevates LDL-C.
Diabetes mellitus: elevates triglycerides, low HDL-C.
Nephrotic syndrome: profound LDL-C elevation.
Obstructive liver disease: elevated TC and altered lipoprotein composition.
Drugs: protease inhibitors (especially boosted ritonavir), anabolic steroids, corticosteroids, retinoids, . Once secondary causes are addressed, the lipid profile often improves; persistent abnormalities indicate primary hyperlipidemia requiring long-term management.

Pearl: A non-fasting lipid panel is sufficient for initial screening; only confirm abnormalities with a fasting panel when triglycerides exceed 200 mg/dL or when initiating pharmacotherapy.

Severity Staging and Risk Stratification

▸Global risk scores (PCE, SCORE, QRISK) categorize 10-year ASCVD risk and determine statin initiation thresholds.
▸Risk enhancers such as hsCRP ≥2 mg/L, CKD, and Lp(a) >50 mg/dL refine intermediate-risk patients.
▸Genetic testing for LDLR mutations reclassifies up to 19.6% of FCH patients, guiding cascade screening and high-intensity therapy.

HY High Yield: In patients with LDL-C ≥190 mg/dL, treat as familial hypercholesterolemia regardless of global risk score; cascade screening of first-degree relatives is mandatory.

Once the lipid profile and underlying etiology are established, the next step is to quantify global cardiovascular risk to determine the intensity and timing of lipid-lowering therapy. Risk stratification relies on validated scores that integrate traditional risk factors, lipid levels, and emerging biomarkers.

Global

Multinational guidelines recommend estimating 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations (PCE; ACC/AHA), SCORE (ESC), or QRISK (UK). These scores incorporate age, sex, total cholesterol, HDL-C, smoking status, systolic blood pressure, diabetes, and treatment. Risk categories guide statin initiation: low (<5%), borderline (5-7.5%), intermediate (7.5-20%), and high (≥20%). Patients with established ASCVD, diabetes with target organ damage, LDL-C ≥190 mg/dL, or chronic kidney disease (CKD) are automatically classified as high risk regardless of score.

Risk enhancers further refine intermediate-risk patients. High-sensitivity C-reactive protein (hsCRP) ≥2 mg/L identifies residual inflammatory risk; in the JUPITER trial, 20 mg reduced first cardiovascular events by 45% (HR 0.55, 95% CI 0.38-0.82) among individuals with LDL-C <130 mg/dL, hsCRP ≥2 mg/L, and moderate CKD (eGFR <60 mL/min/1.73 m²) ^[129]^A1b. Other enhancers include lipoprotein(a) >50 mg/dL, family history of premature ASCVD, metabolic syndrome, and chronic inflammatory conditions.

Severe Hyperlipidemia and Genetic Syndromes

LDL-C ≥190 mg/dL or triglycerides ≥500 mg/dL define severe phenotypes that warrant aggressive therapy irrespective of global risk score. Genetic testing can reclassify patients with suspected familial (FH). Among patients with a clinical diagnosis of familial combined hyperlipidemia (FCH), 19.6% harbored LDL receptor (LDLR) mutations; total cholesterol ≥335 mg/dL and apolipoprotein B ≥185 mg/dL were the best thresholds for predicting a mutation ^[117]^C4. Identifying FH carriers mandates cascade screening and high-intensity statin plus .

Emerging Risk Stratification Tools

Imaging-based measures add prognostic information beyond traditional anthropometrics. The visceral-to-subcutaneous adipose tissue (VAT/SAT) ratio, quantified from whole-body MRI, improved risk classification for major adverse cardiovascular events (MACE) over waist circumference (net reclassification improvement [NRI] 0.088, 95%) and independently predicted MACE (aHR 1.30) ^[22]^B2b. The uric acid-to-HDL cholesterol ratio (UHR) has emerged as an independent predictor of heart failure outcomes, with a nonlinear dose-response relationship ^[136]^B2b.

Pearl: For intermediate-risk patients (10-year ASCVD risk 7.5-20%), measure hsCRP and consider coronary artery calcium scoring; a CAC score of zero can reclassify many to low risk and defer statin therapy, while hsCRP ≥2 mg/L or CAC >100 justifies treatment escalation.

Risk Categories and Treatment Thresholds

Risk Category	10-Year ASCVD Risk	LDL-C Threshold for Statin	Key Enhancers
Low	<5%	≥190 mg/dL	None
Borderline	5-7.5%	≥190 mg/dL or risk enhancers	hsCRP ≥2 mg/L, family history, metabolic syndrome
Intermediate	7.5-20%	≥70 mg/dL (consider if ≥100)	CAC >100, hsCRP ≥2, CKD, Lp(a) >50
High	≥20% or ASCVD/diabetes/CKD/LDL-C ≥190	Any LDL-C (initiate statin)	All above plus established ASCVD

Acute and Initial Management

▸High-intensity statin should be initiated immediately in all patients with established ASCVD, as it reduces mortality and cardiovascular events.
▸Triglycerides ≥500 mg/dL require urgent fibrate therapy to prevent acute pancreatitis.
▸Initial management must include monitoring of lipid levels and tolerability within 4-12 weeks.

Rx Drug of Choice: For ASCVD: **atorvastatin 40-80 mg or rosuvastatin 20-40 mg** initiated immediately. For severe hypertriglyceridemia: **fenofibrate 160 mg daily**.

! Warning: Do NOT delay statin in acute coronary syndrome awaiting lipid panel; the benefit is time-sensitive. Monitor for myopathy and transaminitis after initiation.

Once the severity of hyperlipidemia has been categorized, whether as moderate-risk primary prevention, established atherosclerotic cardiovascular disease (ASCVD), or severe , acute initial splits into two distinct pathways: immediate high-intensity statin therapy for all patients with ASCVD, and urgent triglyceride-lowering therapy for those with triglycerides ≥500 mg/dL to prevent pancreatitis.

Step 1: Identify Urgency

ASCVD (acute coronary syndrome, stroke, peripheral arterial disease): Initiate statin therapy regardless of baseline LDL-C level. Statin therapy reduces all-cause mortality (RR 0.86, 95% CI 0.80-0.93), cardiovascular mortality (RR 0.69, 95% CI 0.54-0.88), and myocardial infarction (RR 0.64, 95% CI 0.57-0.71) ^[46]^A1a (1a).
Severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL): Initiate triglyceride-lowering therapy urgently; such levels confer risk of acute pancreatitis. Fibrates (e.g., ) are first-line. In mixed hyperlipidemia, fenofibrate plus reduces LDL-C by -22% vs -9% with fenofibrate alone (p < 0.001) and also improves triglycerides and HDL-C ^[141]^A1b (1b).

Figure 1: Acute initial management pathway.

Step 2: First-Line Pharmacotherapy

For severe hypertriglyceridemia: Begin (starting dose 160 mg daily) or, if mixed hyperlipidemia, the combination fenofibrate 160 mg plus ezetimibe 10 mg. The co-administration is well tolerated and more effective than fenofibrate alone over 48 weeks ^[141]^A1b. Novel siRNA therapies such as (an APOC3 inhibitor) reduced triglycerides by 49.8-62.4 percentage points versus placebo at week 24 in mixed hyperlipidemia ^[144]^A1b (1b), but these agents are not yet first-line acute therapy.

Step 3: Initiate and Titrate

Start with a moderate lipid-lowering effect; titrate to achieve guideline targets (e.g., LDL-C <70 mg/dL in ASCVD). The DESCARTES trial showed that evolocumab added to various statin backgrounds further reduced LDL-C by 48.5-61.6% ^[143]^A1b (1b), indicating that if goal not reached on statin alone, a PCSK9 inhibitor can be considered in the initial phase for very high-risk patients.
Monitor hepatic transaminases and creatine kinase at 4-12 weeks after starting or dose-escalating statin.

Step 4: Monitoring and Transition

Reassess lipid panel 4-12 weeks after initiation. If triglycerides remain ≥500 mg/dL despite fibrate, consider adding high-dose fish oil or icosapent ethyl.
Once stable, transition from acute to long-term guideline-directed therapy (covered in the next section). Maintain adherence; a cap on prescription benefits leads to poorer LDL-C control (OR for LDL-C ≥130 mg/dL: 1.13, 95% CI 1.03-1.25) ^[152]^B2b (2b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Should a statin be initiated immediately in ACS regardless of baseline LDL?	AHA/ACC, yes, high-intensity statin started within 24 hours	Some European guidelines, allow delay until in-patient discharge if LDL unknown	Mild (timing difference only)	US practice tends to start in the ED or catheterization laboratory; European practice may wait for fasting lipid panel. Both agree on high-intensity statin eventually.
Role of fibrates in preventing pancreatitis in severe hypertriglyceridemia	ADA, fibrates first-line for TG ≥500 mg/dL	NICE, consider fibrate but also lifestyle; no strong trial evidence for pancreatitis reduction	Moderate (different emphasis on evidence strength)	Clinical practice universally uses fibrates for severe HTG; NICE recommends but with caveat of limited endpoint data.

Pearl: In every patient with newly diagnosed ASCVD, start a high-intensity statin immediately regardless of LDL-C level; for patients with triglycerides ≥500 mg/dL, begin a fibrate urgently to reduce the risk of acute pancreatitis. Both interventions are supported by strong evidence and should not be delayed.

First-Line Drug Dosing for Acute Initial Management

Indication	Starting Dose	Key Evidence
ASCVD	40-80 mg daily	RR 0.64 for MI (95% CI 0.57-0.71) ^[46]^A1a
ASCVD (alternative)	20-40 mg daily	Similar efficacy to atorvastatin ^[46]^A1a
Severe hypertriglyceridemia	160 mg daily	LDL-C reduction -22% with ezetimibe add-on ^[141]^A1b
Mixed hyperlipidemia (add-on)	10 mg daily	Additional -13% LDL-C over fenofibrate alone ^[141]^A1b

Long-term Guideline-Directed Therapy

▸High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) is the cornerstone of long-term therapy, reducing all-cause mortality by 14% and MI by 36% in primary prevention meta-analyses.
▸Add ezetimibe 10 mg as first combination agent; then escalate to PCSK9 inhibitor (evolocumab 420 mg SC q4w or inclisiran 300 mg SC q6mo) or bempedoic acid 180 mg when LDL-C targets are not met.
▸Avoid policosanol (ineffective), do not discontinue statins for mild myalgias without formal rechallenge, and monitor adherence at every visit, a drug cap in Medicare doubled the odds of LDL-C >130 mg/dL.

Rx Drug of Choice: First-line long-term therapy: **atorvastatin 40-80 mg daily** or **rosuvastatin 20-40 mg daily**, plus **ezetimibe 10 mg daily** if LDL-C remains above goal [46] (1a).

! Warning: Do not co-administer gemfibrozil with statins because of markedly elevated risk of rhabdomyolysis. Fenofibrate is the preferred fibrate for combination therapy.

After initial stabilization of acute coronary syndrome or the decision to initiate pharmacotherapy in primary prevention, the central task becomes achieving and maintaining guideline-directed lipid targets through a stepwise, treat-to-target strategy. Long-term therapy is anchored by high-intensity , with escalation to combination therapy when goals are not met. A 2023 Global Diagnostics Network analysis of nearly half a billion lipid results found that mean LDL-C peaks at 50-59 years in women and 40-49 years in men, with wide inter-country variation, underscoring the gap between population-level burden and contemporary treatment ^[17]^B2c (2c).

Step 1: Initiate and maximize statin therapy

High-intensity statins ( 40-80 mg or 20-40 mg) are recommended for all patients with clinical ASCVD and for those with primary severe (LDL-C ≥190 mg/dL). In a meta-analysis of 19 primary prevention trials (n=71,344), statin therapy reduced all-cause mortality (RR 0.86, 95% CI 0.80-0.93; absolute risk reduction 0.40%), cardiovascular mortality (RR 0.69, 95% CI 0.54-0.88; ARR 0.43%), and myocardial infarction (RR 0.64, 95% CI 0.57-0.71; %) ^[46]^A1a (1a). The same analysis found no significant increase in serious adverse events (RR 0.99, 95% CI 0.94-1.04), myalgia (RR 0.96, 95% CI 0.79-1.16), or (RD 0.4 per 1000 patients, 95% CI -0.1 to 0.9) ^[43]^A1a (1a). Transaminase elevation >3× ULN was marginally increased (RD 4.2 per 1000, 95% CI 1.5-6.9) but did not translate into clinical hepatitis ^[43]^A1a. For patients aged ≥75 years, a post hoc analysis from phase 3 bempedoic acid trials confirmed that LDL-C lowering efficacy (-18.3% to - placebo-corrected) and safety are comparable to younger subgroups ^[164]^A1b (1b).

Do not discontinue statins for mild, non-progressive myalgias without a dechallenge-rechallenge trial. A systematic review found that the absolute excess risk of myalgia with statins versus placebo is only 2.7 per 1000 patients (95% CI -3.2 to 8.7) in double-blind trials ^[43]^A1a. Exercise training can be safely undertaken by statin users without worsening symptoms, and may even improve quality of life in those with muscle complaints ^[163]^B2b (2b).

Step 2: Add when LDL-C remains above goal

Ezetimibe 10 mg daily is the first add-on because of low cost, once-daily dosing, and proven cardiovascular benefit when added to statin therapy. In the SEAS trial (n=1873), 40 mg plus ezetimibe 10 mg reduced ischemic cardiovascular events compared with placebo (HR 0.78, 95% CI 0.63-0.97) over 52 months, although it did not slow progression of ^[42]^A1b (1b). The 48-week extension of a fenofibrate-ezetimibe co-administration study (n=576) demonstrated that ezetimibe plus fenofibrate reduced LDL-C by -22% versus -9% with fenofibrate alone (p<0.001), while also improving triglycerides and HDL-C ^[141]^A1b (1b). Ezetimibe is well tolerated, with no excess of myopathy or transaminase elevation in long-term co-administration.

Drug	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Atorvastatin	10-20 mg PO daily	80 mg daily	No adjustment	Avoid in active liver disease	Baseline ALT, CK; lipid panel at 12 weeks
Rosuvastatin	5-10 mg PO daily	40 mg daily	eGFR <30: start 5 mg, max 10 mg	C: avoid	As above
Ezetimibe	10 mg PO daily	10 mg daily	No adjustment	No dose adjustment	None routine
Bempedoic acid	180 mg PO daily	180 mg daily	eGFR 15-30: avoid if not on statin; on statin, use with caution	Child-Pugh C: avoid	hsCRP, uric acid
Evolocumab	140 mg SC every 2 weeks or 420 mg SC every 4 weeks	420 mg q4w	No adjustment	No adjustment	LDL-C at 12 weeks
Inclisiran	300 mg SC once , then 300 mg at 3 months, then every 6 months	300 mg SC q6mo	No adjustment	No adjustment	LDL-C at 6 months

Step 3: Add PCSK9 inhibitor or bempedoic acid for very high risk or statin intolerance

If LDL-C remains ≥70 mg/dL (or ≥55 mg/dL in extreme risk) despite maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is the next step. In the DESCARTES trial (n=901, 52 weeks), evolocumab 420 mg every 4 weeks added to background atorvastatin with or without ezetimibe reduced LDL-C by 57.0%±2.1% from baseline (p<0.001), consistent across all background therapy strata ^[143]^A1b (1b). In BEIJERINCK (n=464), evolocumab achieved LDL-C <70 mg/dL in 73.3% of HIV-infected patients versus 7.9% with placebo, with no excess adverse events ^[37]^A1b (1b). In adolescents with homozygous FH, inclisiran (300 mg at days 1, 90, 270) reduced LDL-C by - (95% CI -59.2 to -7.3) versus placebo, with 55.6% achieving >20% LDL-C reduction and no serious adverse events ^[3]^A1b (1b).

For patients with statin intolerance, bempedoic acid 180 mg daily is an effective alternative. In CLEAR-Outcomes (n=13,970 statin-intolerant patients), bempedoic acid reduced LDL-C by 21.1% and hsCRP by 21.6% at 6 months compared with placebo ^[8]^B2b (1b). Baseline hsCRP quartile was a stronger predictor of future cardiovascular events than baseline LDL-C quartile (HR 1.43 versus 1.19 for the primary composite end point), but bempedoic acid’s benefit was consistent across all strata ^[8]^B2b (2b).

Step 4: Manage

For fasting triglycerides persistently >500 mg/dL after statin optimization, add a fibrate or prescription fish oil. The MUIR trial (n=353) showed that plozasiran - an APOC3 siRNA - reduced triglycerides by -49.8 to -62.4 percentage points at 24 weeks compared with placebo in mixed hyperlipidemia, with no increase in LDL particle number ^[144]^A1b (1b). Zodasiran, an ANGPTL3 RNAi, reduced triglycerides by -51 to -63 percentage points and non-HDL-C by -29 to -36 percentage points across doses ^[142]^A1b (1b). Although these agents are not yet approved, they highlight the emerging potential of RNA-based therapies for refractory hypertriglyceridemia.

Step 5: Monitor adherence and adjust every 3-12 months

Annual lipid panels suffice once targets are stable. A cap on medication benefits was associated with 27% higher odds of nonadherence to statin therapy and 13% higher odds of LDL-C >130 mg/dL in a Medicare cohort, reinforcing that cost and access barriers directly worsen outcomes ^[152]^B2b (2b). Use nonfasting lipid panels for convenience; if triglycerides are >400 mg/dL, repeat fasting. Do not use policosanol, as a randomized controlled trial showed no LDL-C reduction beyond placebo at doses up to 80 mg/day ^[147]^A1b (1b).

What NOT to do

Do not use policosanol for lipid lowering. In a multicenter, placebo-controlled trial (n=143), no dose of policosanol (10-80 mg/day) reduced LDL-C more than 10%, and there was no dose-response relationship ^[147]^A1b (1b).
Do not routinely co-administer gemfibrozil with statins because of increased risk of rhabdomyolysis. Fenofibrate is the preferred fibrate for combination therapy.
Do not withhold statins for isolated ALT elevations <3× ULN in the absence of active liver disease; the excess risk of transaminase elevation is small and not associated with clinical hepatitis (RD 4.2 per 1000) ^[43]^A1a (1a).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
First add-on after statin maximization	ACC/AHA 2018 - ezetimibe is first-line add-on	ESC/EAS 2019 - ezetimibe is first add-on but PCSK9i may be considered earlier in very high risk	Mild (both recommend ezetimibe first; ESC allows early PCSK9i in extreme risk) ^[143]^A1b^[164]^A1b	Most patients should start ezetimibe; reserve PCSK9i for those with FH, clinical ASCVD on maximal therapy, or statin intolerance
Treatment target	ACC/AHA - no specific LDL-C target; treat to intensity	ESC/EAS - treat to goal: <55 mg/dL in very high risk, <70 mg/dL in high risk	Moderate (different philosophies of treat-to-target vs treat-to-intensity) ^[46]^A1a^[143]^A1b	In practice, use treat-to-target for high-risk patients; ACC/AHA approach may simplify for primary prevention
Role of bempedoic acid	US centers - increasingly used as first alternative in statin intolerance	European centers - still position as third-line after ezetimibe and PCSK9i	Mild (cost and approval differences) ^[8]^B2b^[164]^A1b	Bempedoic acid is a valuable second-line option for statin intolerance; consider in high-risk elderly patients

Pearl: In patients with ASCVD, achieve LDL-C <55 mg/dL through a stepwise algorithm: start high-intensity statin, add ezetimibe if not at goal at 12 weeks, then advance to a PCSK9 inhibitor (evolocumab or inclisiran) for those who remain above threshold; bempedoic acid is an effective alternative in statin-intolerant patients, with -21.1% LDL-C reduction and -21.6% hsCRP reduction in CLEAR-Outcomes ^[8]^B2b.

Interventional and Device Therapy

▸Lipoprotein apheresis is the definitive interventional therapy for HoFH and severe HeFH refractory to pharmacotherapy, achieving 60-70% acute LDL-C reduction.
▸In multivessel coronary artery disease, CABG is associated with lower mortality and MACE compared with PCI, independent of diabetic status.
▸Post-revascularization lipid management is critical to reduce stent thrombosis, graft failure, and disease progression.

For patients who remain at very high risk despite maximal pharmacotherapy, interventional options provide additional lipid-lowering and risk reduction. The primary procedural therapy for hyperlipidemia is lipoprotein apheresis, while revascularization procedures address established atherosclerotic cardiovascular disease (ASCVD) in this population.

Lipoprotein Apheresis

Lipoprotein apheresis is indicated for homozygous familial (HoFH) and severe heterozygous FH (HeFH) with inadequate LDL-C reduction on maximal drug therapy, including high-intensity , , and . The procedure selectively removes apolipoprotein B-containing lipoproteins via dextran sulfate adsorption, -induced precipitation, or immunoadsorption, achieving acute LDL-C reductions of 60-70%. Treatment is typically performed every 1-2 weeks, with the goal of maintaining LDL-C < 100 mg/dL (or < 70 mg/dL in patients with established ASCVD). Long-term registry data demonstrate that regular apheresis reduces cardiovascular event rates by approximately 70% compared with historical controls, though no randomized trials exist. Patient selection requires documented failure of pharmacotherapy, commitment to lifelong treatment, and adequate vascular access.

Revascularization in Hyperlipidemic Patients

Hyperlipidemia is a major driver of coronary and aortic valve disease, and revascularization is frequently required. In patients with unprotected left main coronary artery stenosis, drug-eluting stents (DES) reduce the need for repeat revascularization compared with bare-metal stents (BMS) (target lesion revascularization 5.4% vs 12.1% at 3 years; HR 0.40, 95% CI 0.22-0.73) without increasing death or myocardial infarction ^[175]^B2b. For multivessel coronary artery disease, ( ) is associated with lower long-term mortality (HR 0.85; P=0.001) and major adverse cardiovascular events (HR 0.51; P<0.0001) compared with percutaneous coronary intervention (PCI), regardless of diabetic status ^[161]^B2b. In patients with severe and hyperlipidemia, transcatheter aortic valve implantation (TAVI) achieves 1-year survival of 76.1% overall (81.1% transfemoral, 72.1% transapical) ^[177]^C4. Post-revascularization, aggressive lipid-lowering therapy is essential to reduce stent thrombosis, graft failure, and progression of native disease.

Comparative Outcomes of Revascularization Strategies

Procedure	Outcome	Effect estimate	95% CI	P value	Reference
DES vs BMS (left main)	Target lesion revascularization	HR 0.40	0.22-0.73	0.003	^[175]^B2b
DES vs BMS (left main)	Death	HR 0.71	0.36-1.40	0.976	^[175]^B2b
CABG vs PCI (multivessel)	Death	HR 0.85	,	0.001	^[161]^B2b
CABG vs PCI (multivessel)	MACE	HR 0.51	,	<0.0001	^[161]^B2b
TAVI (overall)	1-year survival	76.1%	,	,	^[177]^C4

Pearl: Lipoprotein apheresis should be considered for HoFH patients who fail to achieve LDL-C < 100 mg/dL on maximal drug therapy; for hyperlipidemic patients requiring revascularization, CABG may offer a survival advantage over PCI in multivessel disease, and aggressive statin therapy is mandatory post-procedure to prevent recurrent events.

History and Evolution of Treatment

▸Rosuvastatin 20 mg in JUPITER reduced major CV events by 44% (HR 0.56) among individuals with elevated hs-CRP, NNT ~95 over 1.9 years.
▸Dietary supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice) showed no significant LDL-C reduction vs placebo in the SPORT trial; guggulipid raised LDL-C and policosanol was no better than placebo.
▸PCSK9 inhibition evolved from injectable monoclonal antibodies (evolocumab 57% LDL-C reduction) to siRNA (inclisiran, -33.3% in HoFH adolescents) to oral small molecules (laroprovstat 51% on top of rosuvastatin, achieving 80% total LDL-C reduction).

! Warning: Bococizumab was abandoned after phase 3 development due to high rates of antidrug antibodies that markedly attenuated LDL-C lowering and resulted in no cardiovascular benefit (HR 0.96). In contrast, evolocumab (a fully human monoclonal) and inclisiran (siRNA) show durable, consistent efficacy with minimal immunogenicity.

Interventional and device-based therapies target advanced atherosclerotic disease, but the vast reduction in cardiovascular mortality over the past three decades stems from pharmacologic innovation grounded in landmark trials.

Statin Monotherapy: The Foundational Era

The modern era began with the discovery of HMG-CoA reductase inhibitors. Early trials established as the cornerstone of lipid . The JUPITER trial enrolled 17,802 apparently healthy individuals with LDL-C <130 mg/dL and high-sensitivity C-reactive protein ≥2.0 mg/L, randomizing them to 20 mg daily or placebo. The trial was stopped early after a median 1.9 years because of a 44% relative risk reduction in major cardiovascular events (HR 0.56, 95% CI 0.46-0.69; rates 0.77 vs 1.36 per 100 person-years); the NNT was approximately 95 to prevent one primary event ^[39]^A1b. Rosuvastatin reduced LDL-C by 50% and hs-CRP by 37%. Previously, the AFCAPS/TexCAPS trial (not provided) had shown that lovastatin reduced first acute coronary events in primary prevention among individuals with average LDL-C but elevated CRP; a post-hoc analysis of that trial demonstrated that lovastatin reduced CRP by 14.8% (P<0.001) and was effective in those with low LDL-C/high CRP (NNT 43 over 5 years) ^[202]^A1b. Among patients with established ASCVD, pravastatin 40 mg reduced LDL particle concentration by 19% as measured by NMR, an effect magnified in those with the smallest baseline LDL particle size ^[199]^A1b. These data solidified the statin class as first-line therapy across both primary and secondary prevention populations ^[215]^D5.

The Combination Therapy Era and Abandoned Approaches

Combination therapy emerged to address residual risk. The SEAS trial randomized 1,873 patients with asymptomatic to 40 mg plus 10 mg vs placebo. The combination did not reduce the primary composite outcome (HR 0.96, 95% CI 0.83-1.12) but did reduce ischemic cardiovascular events (HR 0.78, 95% CI 0.63-0.97; P=0.02), though cancer occurred more frequently in the active arm (105 vs 70, P=0.01) ^[42]^A1b. In mixed hyperlipidemia, fenofibrate plus ezetimibe produced greater LDL-C reduction than fenofibrate alone (-22% vs -9%) with similar tolerability over 48 weeks ^[141]^A1b. Niacin extended-release was added to ezetimibe/simvastatin in a 24-week trial, yielding superior lipid improvements, but 25% of patients discontinued due to flushing, limiting its clinical utility ^[195]^A1b. Subsequently, large outcomes trials failed to show incremental cardiovascular benefit from niacin when added to statins, and niacin combination therapy was largely abandoned.

Similarly, dietary supplements were tested -to-head. The SPORT trial randomized 190 participants to rosuvastatin 5 mg, placebo, or six common supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice). Rosuvastatin reduced LDL-C by ** more than placebo** (P<0.001); no supplement produced a significant LDL-C reduction ^[111]^A1b. Guggulipid, an herbal extract, actually raised LDL-C by 4-5% compared with placebo (-5% LDL-C), with hypersensitivity rash in 6 of 67 treated patients ^[204]^A1b. Policosanol (sugar cane-derived) at doses 10-80 mg/day showed no significant LDL-C reduction beyond placebo in a 12-week trial ^[147]^A1b. These results decisively refuted popular alternative therapies.

The PCSK9 Revolution: Monoclonal Antibodies, siRNA, and the First Oral Agent

The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a key LDL receptor regulator opened a new therapeutic axis. The DESCARTES trial demonstrated that evolocumab 420 mg every 4 weeks reduced LDL-C by 57% at 52 weeks across various background statin intensities (range 48.5-61.6%; P<0.001 for each) ^[143]^A1b. In the BEIJERINCK trial among HIV-infected patients, evolocumab reduced LDL-C by 56.9% (95% CI 61.6% to 52.3%) vs placebo, with 73.3% achieving LDL-C <70 mg/dL vs 7.9% on placebo ^[37]^A1b. However, bococizumab, a humanized monoclonal PCSK9 antibody, was found to induce high-titer antidrug antibodies in a substantial proportion of patients, markedly attenuating LDL-C reduction and causing wide variability in effect; the cardiovascular outcome analysis showed no benefit (HR 0.96, 95% CI 0.66-1.39), and the drug was withdrawn from development ^[145]^A1b.

The RNA interference (siRNA) platform provided a solution requiring infrequent dosing. Inclisiran, a liver-targeted siRNA against PCSK9, was studied in adolescents with homozygous familial (HoFH) in the ORION-13 trial. The placebo-adjusted LDL-C reduction at day 330 was -33.3% (95% CI - to -7.3%), with 55.6% of inclisiran-treated patients achieving >20% reduction vs none on placebo ^[3]^A1b. An oral small-molecule PCSK9 inhibitor, laroprovstat (AZD0780), entered phase 1 testing. It increases LDL receptor expression by stabilizing the PCSK9 C-terminal domain rather than blocking the LDLR interaction. At a dose of 30 mg once daily, added to rosuvastatin 20 mg, laroprovstat achieved an 80% total LDL-C reduction (29% from rosuvastatin plus 51% from laroprovstat), with a half-life of ~40 hours suitable for once-daily dosing ^[139]^A1b.

Beyond LDL-C: ANGPTL3, APOC3, and Lp(a) Targets

Angiopoietin-like 3 (ANGPTL3) and apolipoprotein C3 (APOC3) emerged as targets for patients with mixed hyperlipidemia or . Zodasiran, an RNAi therapy targeting ANGPTL3, reduced triglycerides in a dose-dependent manner in the ARCHES-2 trial: placebo-adjusted reductions of -51 to -63 percentage points at week 24 (P<0.001), with non-HDL cholesterol reductions of -29 to -36 percentage points and LDL-C -14 to -20 percentage points. Transient HbA1c elevation occurred at the highest dose ^[142]^A1b. SHR-1918, a fully human monoclonal ANGPTL3 antibody, added to standard therapy reduced LDL-C by 21.7-29.9% (dose dependent) and also lowered triglycerides ^[35]^A1b. Plozasiran, an siRNA targeting APOC3, reduced fasting triglycerides by 49.8-62.4 percentage points in the MUIR trial (P<0.001 for all doses) and favorably shifted LDL particle size from small dense to larger, less atherogenic particles without increasing apolipoprotein B ^[144]^A1b^[140]^A1b. These agents represent a paradigm shift for patients with significant residual lipemic risk despite statin therapy.

The Gene Editing Horizon

The American College of Cardiology 2026 Scientific Statement on gene editing described emerging CRISPR-Cas9-based approaches for monogenic cardiovascular diseases, including variants of severe hypercholesterolemia and amyloidosis. Lipid nanoparticle delivery systems targeting hepatocytes have made liver-edited therapies for homozygous familial hypercholesterolemia a realistic goal, with curative intent on the horizon ^[191]^A1c.

Pearl: The history of hyperlipidemia therapy is one of progressive replacement, ineffective supplements and flawed antibodies yielded to precisely targeted statins, , and RNAi agents; the NNT for rosuvastatin in primary prevention was ~95 ^[39]^A1b, while combination statin plus laroprovstat can achieve an 80% LDL-C reduction from baseline ^[139]^A1b.

Landmark Trials in the Evolution of Hyperlipidemia Therapy

Therapy	Trial	Key Result	Ref
Rosuvastatin 20 mg	JUPITER	Primary endpoint HR 0.56 (95% CI 0.46-0.69); LDL-C -50%, hs-CRP -37%	^[39]^A1b
Lovastatin	AFCAPS/TexCAPS post-hoc	NNT 43 in low-LDL/high-CRP subgroup	^[202]^A1b
Simvastatin/ezetimibe	SEAS	No reduction in aortic stenosis composite; ischemic events HR 0.78 (P=0.02)	^[42]^A1b
Evolocumab 420 mg Q4W	DESCARTES	LDL-C -57% (range 48.5-61.6%) at 52 weeks	^[143]^A1b
Bococizumab 150 mg Q2W	SPIRE	Antidrug antibodies attenuated efficacy; CV events HR 0.96 (95% CI 0.66-1.39)	^[145]^A1b
Inclisiran 300 mg	ORION-13 (HoFH adolescents)	Placebo-adjusted LDL-C -33.3% (95% CI -59.2 to -7.3%) at day 330	^[3]^A1b
Laroprovstat 30 mg + rosuvastatin 20 mg	Phase 1	LDL-C -51% from laroprovstat; total -80% (including statin run-in)	^[139]^A1b
Zodasiran 200 mg	ARCHES-2	TG -63 pp vs placebo; non-HDL-C -36 pp	^[142]^A1b
Plozasiran 50 mg	MUIR	TG -62.4 pp vs placebo; shift to large LDL particles	^[144]^A1b^[140]^A1b
SHR-1918 600 mg Q4W	Phase 2	LDL-C -29.9% vs placebo on top of standard therapy	^[35]^A1b

Complications

▸Severe hypertriglyceridemia (>1000 mg/dL) is a direct cause of acute pancreatitis and requires aggressive lipid-lowering therapy.
▸Statin therapy rarely causes significant muscle toxicity in clinical trials (RD 2.7/1000 for myalgia), but high-intensity statins increase diabetes risk (RR 1.25).
▸Several non-lipid drugs (lorlatinib, temsirolimus, JAK inhibitors) can induce hyperlipidemia, mandating routine lipid monitoring and potential add-on therapy.

The evolution from early statin trials to modern has transformed lipid , yet both the underlying disease and its therapies carry significant complications that require recognition and active surveillance.

Disease-Related Complications

Severe (triglycerides > 1000 mg/dL) can precipitate acute pancreatitis through free fatty acid-induced pancreatic acinar injury; management requires aggressive lipid-lowering with fibrates, omega-3 fatty acids, and, in refractory cases, insulin or plasmapheresis ^[219]^C4. Marked hypertriglyceridemia may also manifest as lipemic aqueous humor causing pseudouveitis, which resolves with rapid metabolic correction ^[29]^C4. Chronic hyperlipidemia drives atherosclerotic cardiovascular disease, heart failure, and stroke through mechanisms detailed in earlier sections, but the acute complications of extreme elevations demand prompt intervention.

Therapy-Related Complications

Statin therapy is generally well tolerated, but a systematic overview of 35 trials (74,102 subjects) found a small excess risk of transaminase elevations (absolute risk difference 4.2 per 1000, 95% CI 1.5-6.9), while myalgia, creatine kinase elevations, and were not significantly increased compared with placebo ^[43]^A1a. In primary prevention populations, high-intensity were associated with an increased risk of new-onset diabetes (RR 1.25, 95% CI 1.05-1.49) ^[46]^A1a. Bempedoic acid shows comparable safety across age groups, including those aged ≥75 years, without excess muscle or hepatic events ^[164]^A1b. PCSK9 inhibitors such as bococizumab have been limited by injection-site reactions (12.7 per 100 person-years) and development of antidrug antibodies that attenuate LDL-C lowering ^[145]^A1b. Several non-lipid drugs can induce or worsen hyperlipidemia: the ALK inhibitor lorlatinib caused grade 3/4 hyperlipidemia in 72% of patients (primarily altered lipid levels) ^[38]^A1b; the mTOR inhibitor temsirolimus also elevates lipids (along with hyperglycemia and rash) ^[41]^A1b; JAK inhibitors ^[92]^B2a and certain monoclonal antibodies ^[213]^A1b similarly raise lipid levels. Monitoring of lipid panels is essential during therapy with these agents, and statin or should be added if thresholds are exceeded.

Therapy	Common Adverse Effects	Frequency	Management
Statins (high-intensity)	Myalgia, CK elevation, transaminitis, new-onset diabetes	Myalgia: not significantly increased vs placebo; transaminitis: RD 4.2/1000; diabetes: RR 1.25 ^[43]^A1a^[46]^A1a	Discontinue if CK > 10x ULN or transaminases > 3x ULN; switch to lower-potency statin or alternative class
Bempedoic acid	Similar to placebo; possibly uric acid elevation	No excess myalgia or hepatic events ^[164]^A1b	Monitor uric acid; avoid in gout flares
PCSK9 inhibitors (e.g., bococizumab)	Injection-site reactions, antidrug antibodies	12.7 per 100 person-years ^[145]^A1b	Switch to evolocumab/alirocumab; antibodies less common with fully human monoclonal antibodies
Lorlatinib, temsirolimus, JAK inhibitors	Drug-induced hyperlipidemia	Lorlatinib grade 3/4: 72% ^[38]^A1b; temsirolimus: hyperlipidemia, hyperglycemia ^[41]^A1b	Baseline and periodic lipid monitoring; add statin/ezetimibe as needed

Pearl: For any patient presenting with acute pancreatitis and lipemic serum, check triglycerides immediately; a level > 1000 mg/dL requires urgent lipid-lowering, not just supportive care, to halt pancreatic autodigestion ^[219]^C4.

Prognosis and Natural History

▸Untreated hyperlipidemia markedly increases lifetime cardiovascular risk, which is mitigated by statin therapy (RR 0.86 for all-cause mortality in primary prevention).
▸Preoperative PCSK9 inhibitors reduce 30-day MACE compared with statins (NNT=31).
▸Paradoxical protective associations in aortic aneurysm and variant angina likely reflect confounding by statin use, not true protection from hyperlipidemia.

HY High Yield: The greatest modifiable predictor of survival in patients with hyperlipidemia is statin adherence; a pharmacy care program improved adherence from 61% to 97%, with significant BP and LDL-C reductions [83].

! Warning: Do not interpret the paradoxical protective associations of hyperlipidemia in aortic aneurysm and variant angina as license to withhold lipid-lowering therapy; these findings are likely driven by confounding by indication, where treated patients are labelled with the diagnosis.

The lifetime risk of cardiovascular disease is 24% in women and 38% in men when all five classic risk factors, including hyperlipidemia, are present at age 50 ^[59]^B2b. Absence of all five at that age yields more than 13 additional life-years free of CVD for women and more than 10 for men ^[59]^B2b.

Untreated, hyperlipidemia accelerates atherosclerotic progression. Mortality rates rise with increasing obesity, an effect substantially mediated by hyperlipidemia ^[75]^B2b. Patients with hyperlipidemia and healed coronary plaques, markers of prior plaque destabilization, have higher rehospitalization rates ^[106]^B2b.

Treatment markedly improves outcomes. Primary prevention with reduces all-cause mortality by 14% (RR 0.86; 95% CI 0.80-0.93) and major cardiovascular events by 30% ^[46]^A1a. Preoperative PCSK9 inhibitor therapy, compared with statins, lowers 30-day major adverse cardiovascular events from 9.6% to 6.4% (RR 0.67; NNT=31) ^[132]^B2b. A dietary portfolio of cholesterol-lowering foods reduces LDL-C by 13-14% ^[208]^A1b, and bariatric surgery achieves hyperlipidemia remission in 60% of gastric bypass patients ^[146]^B2a.

Paradoxically, hyperlipidemia appears protective in ascending (HR 0.46 for adverse aortic events) ^[57]^B2b and variant angina (OR 0.38 for aborted ) ^[16]^B2b, likely reflecting confounding by statin therapy.

Predictors of adverse outcome include young age at hyperlipidemia onset, clustering with pre-diabetes and pre- (aHR 1.23 for myocardial infarction or stroke over 14 years) ^[223]^B2b, elevated high-sensitivity C-reactive protein ^[39]^A1b, and high visceral-to-subcutaneous adipose tissue ratio ^[22]^B2b.

Pearl: Treating hyperlipidemia with statins reduces all-cause mortality by approximately 14% in primary prevention, but the absolute benefit is largest in patients with higher baseline risk; the relative benefit is consistent across age and sex subgroups ^[46]^A1a.

Impact of Hyperlipidemia on Lifetime Cardiovascular Risk

Risk Factor Status at Age 50	Lifetime CVD Risk (Women)	Lifetime CVD Risk (Men)	Additional Life-Years Free of CVD (Women)	Additional Life-Years Free of CVD (Men)
All five risk factors present	24%	38%	Reference	Reference
No risk factors	Not reported	Not reported	13.3	10.6

Adapted from ^[59]^B2b, risk factors: hypertension, hyperlipidemia, overweight/obesity, diabetes, smoking.

Special Populations and Prevention

▸Pregnancy-related hypertensive disorders independently double CVD risk and warrant early postpartum lipid reassessment.
▸Rosuvastatin 20 mg reduces cardiovascular events and mortality in moderate CKD with elevated hsCRP; guidelines recommend statins in non-dialysis CKD.
▸In elderly patients, bempedoic acid provides similar LDL-C lowering and cardiovascular benefit as in younger patients, with a comparable safety profile.

The natural history of hyperlipidemia diverges sharply across patient subgroups, requiring population-specific modifications to screening thresholds, drug selection, and treatment targets.

Pregnancy

Pregnancy induces progressive maternal hyperlipidemia, triglycerides, total cholesterol, and LDL-C rise substantially, while HDL-C fluctuates ^[99]^D5. (HDP) independently predict future cardiovascular disease, with an adjusted hazard ratio of 1.82 even among women without prepregnancy cardiometabolic risk factors ^[9]^B2b. Acute stroke complicates 1 in 2,222 pregnancy-related hospitalizations, and the prevalence of hyperlipidemia in these events has increased over time ^[13]^B2c. The global incidence of pregnancy-related stroke is 25.38 per 100,000 pregnancies, with dyslipidemia as a significant risk factor ^[224]^A1a. during gestation focuses on lifestyle modification because and fibrates are teratogenic; after delivery, women with HDP should undergo early lipid re-assessment and aggressive primary prevention, as their residual CVD risk approximates that of a decade of aging ^[9]^B2b^[99]^D5.

Chronic Kidney Disease

CKD affects 14.6% of US adults, yet only 12.3% are aware of their kidney diagnosis ^[67]^B2c. Among those with concurrent cardiometabolic disease ( , diabetes, hyperlipidemia, or obesity), CKD prevalence reaches 16.7% ^[67]^B2c. CKD dramatically amplifies cardiovascular event rates: heart failure incidence 22.0 vs 6.2 per 1,000 person-years compared with preserved kidney function ^[70]^B2b. In the JUPITER trial, 20 mg reduced first major cardiovascular events by 45% (HR 0.55, 95% CI 0.38-0.82) and all-cause mortality by 44% (HR 0.56, 95% CI 0.37-0.85) among individuals with moderate CKD (eGFR <60 mL/min/1.73 m²) and elevated hsCRP ^[129]^A1b. Current guidelines endorse statin therapy for non-dialysis-dependent CKD; fibrates and niacin have uncertain benefit due to limited trial data ^[228]^D5. Comprehensive lifestyle management, controlling at least 7 of 8 modifiable risk factors, lowered incident MASLD risk by 64% (HR 0.36, 95% CI 0.16-0.79) in CKD patients, attenuating risk to that of non-CKD controls ^[225]^B2b.

Elderly

Adherence is a central challenge: a pharmacy-care program improved pill-taking from 61.2% to 96.9%, yielding significant reductions in systolic BP and LDL-C ^[83]^A1b. Statin therapy at hospital discharge for heart failure was associated with improved 1-year mortality (HR 0.80, 95% CI 0.76-0.84) in Medicare beneficiaries aged ≥65 years ^[160]^B2b. Bempedoic acid, evaluated in patients aged ≥75 years, produced LDL-C reductions of -18.3% to -24.5% (comparable to younger subgroups) with similar cardiovascular event reduction and no excess adverse events ^[164]^A1b. Polypharmacy is pervasive, 82.3% of elderly HF patients take ≥5 medications, and hyperpolypharmacy (≥10 drugs) increased the composite of cardiovascular death or HF hospitalization by 22% ^[134]^B2b. Smoking remains common in older adults: 28.3% of men aged ≥40 years were current smokers in one cohort, with a mean 26.3 pack-years ^[230]^C4.

Prevention Across Populations

Primary prevention in women must incorporate sex-specific risk enhancers: HDP, gestational diabetes, and premature ^[7]^D5^[9]^B2b. Long-term community-wide programs, such as the Franklin County initiative, achieved a 28.5% absolute increase in cholesterol control and sustained reductions in all-cause mortality over 40 years ^[73]^B2b. Translating these population-level gains into individual care requires systematically integrating pregnancy history, renal function, age-related adherence barriers, and polypharmacy risk into every lipid management decision.

Pearl: After a pregnancy complicated by hypertensive disorder, reassess the lipid profile within 1 year postpartum and initiate statin therapy if LDL-C exceeds guideline thresholds; these women carry a CVD risk equivalent to that of a decade of aging ^[9]^B2b.

Special Populations: Key Modifications for Lipid Management

Population	Key Risk Modifier	Suggested Approach	Evidence Source
Pregnancy	HDP, gestational diabetes	Lifestyle only during gestation; early postpartum statin if indicated	^[9]^B2b, ^[99]^D5, ^[224]^A1a
CKD (eGFR <60)	High CVD event rates	Statin therapy (e.g., rosuvastatin 20 mg); lifestyle optimization	^[129]^A1b, ^[228]^D5, ^[225]^B2b
Elderly (≥65 y)	Adherence, polypharmacy	Pharmacy care programs; bempedoic acid as alternative	^[83]^A1b, ^[160]^B2b, ^[164]^A1b, ^[134]^B2b

References

[1]
McCrindle BW, Urbina EM, Dennison BA et al.. “Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.” Circulation (2007). PMID: 17377073 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[2]
Pasupathy S, Air T, Dreyer RP et al.. “Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.” Circulation (2015). PMID: 25587100 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
[3]
Wiegman A, Peterson AL, Hegele RA et al.. “Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.” Circulation (2025). PMID: 40391436 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[4]
Cooper LA, Marsteller JA, Carson KA et al.. “Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial.” Circulation (2024). PMID: 39008556 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[5]
Paramsothy P, Knopp RH, Bertoni AG et al.. “Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis).” Journal of the American College of Cardiology (2010). PMID: 20846602 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
[6]
Stone GW, Selker HP, Thiele H et al.. “Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials.” Journal of the American College of Cardiology (2016). PMID: 27056772 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
[7]
Cho L, Davis M, Elgendy I et al.. “Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2020). PMID: 32439010 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention
[8]
Ridker PM, Lei L, Louie MJ et al.. “Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.” Circulation (2023). PMID: 37929602 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Complications
[9]
Boyer TM, Barrett RB, Xiong C et al.. “Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.” Circulation (2025). PMID: 41697979 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
[10]
Mosley JD, Benson MD, Smith JG et al.. “Probing the Virtual Proteome to Identify Novel Disease Biomarkers.” Circulation (2018). PMID: 30571344 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
[11]
Jayaraman R, Reinier K, Nair S et al.. “Risk Factors of Sudden Cardiac Death in the Young: Multiple-Year Community-Wide Assessment.” Circulation (2017). PMID: 29269388 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Prognosis and Natural History
[12]
Covani M, Niccoli G, Fujimoto D et al.. “Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome: An Optical Coherence Tomography Analysis.” Journal of the American College of Cardiology (2025). PMID: 40634017 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications
[13]
Elgendy IY, Gad MM, Mahmoud AN et al.. “Acute Stroke During Pregnancy and Puerperium.” Journal of the American College of Cardiology (2020). PMID: 31948647 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention
[14]
Krishnan P, Farhan S, Schneider P et al.. “Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.” Journal of the American College of Cardiology (2022). PMID: 36137674 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
[15]
DeFilippis EM, Singh A, Divakaran S et al.. “Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction.” Journal of the American College of Cardiology (2018). PMID: 29535062 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Prognosis and Natural History
[16]
Ahn JM, Lee KH, Yoo SY et al.. “Prognosis of Variant Angina Manifesting as Aborted Sudden Cardiac Death.” Journal of the American College of Cardiology (2016). PMID: 27386766 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
[17]
Martin SS, Niles JK, Kaufman HW et al.. “Lipid distributions in the Global Diagnostics Network across five continents.” European heart journal (2023). PMID: 37392135 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy
[18]
Ditkofsky N, Hanna T. “Images in Clinical Medicine. Spontaneous Retropharyngeal Hematoma.” The New England journal of medicine (2016). PMID: 26789902 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
[19]
Otto CM, Newby DE, Hillis GS. “Calcific Aortic Stenosis: A Review.” JAMA (2024). PMID: 39527048 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
[20]
Tilg H, Petta S, Stefan N et al.. “Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.” JAMA (2026). PMID: 41212550 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[21]
McFarland R, Hyslop LA, Feeney C et al.. “Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.” The New England journal of medicine (2025). PMID: 40689593 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention
[22]
Bogner B, Jung M, Reisert M et al.. “Opportunistic screening for incident cardiometabolic disease in metabolically healthy non-obese individuals: a prospective cohort study.” Cardiovascular diabetology (2026). PMID: 42387503 ↗
L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History
[23]
Wabnitz AM. “Management of Large Artery Atherosclerosis.” Continuum (Minneapolis, Minn.) (2026). PMID: 42233827 ↗
L5CASE_REPORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[24]
Qiao Y, Suri FK, Zhang Y et al.. “Racial Differences in Prevalence and Risk for Intracranial Atherosclerosis in a US Community-Based Population.” JAMA cardiology (2017). PMID: 29094154 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy
[25]
van Rosendael AR, Narula J, Lin FY et al.. “Association of High-Density Calcified 1K Plaque With Risk of Acute Coronary Syndrome.” JAMA cardiology (2020). PMID: 31968065 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment
[26]
O'Connor KD, Brophy T, Fonarow GC et al.. “Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure.” Circulation. Heart failure (2020). PMID: 32207996 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[27]
Yeh CF, Ianalieva L, Wong HK et al.. “Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.” Journal of biomedical science (2026). PMID: 42069590 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation
[28]
Atalla M, Gupta V, Khalid M et al.. “Cardiology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974015 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation
[29]
Lei J, Lu X, Liang Q. “Lipemic anterior chamber mimicking uveitis in severe hypertriglyceridemia: a case report and literature review.” BMC ophthalmology (2026). PMID: 42087131 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Complications
[30]
Alzoubi M, Omar Saleh A, Omari FA et al.. “Asymptomatic gallstones: Cumulative incidence proportion, incidence rate, and risk factors for symptoms development: Systematic review and meta-analysis.” PloS one (2026). PMID: 41886405 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation
[31]
Kayani AMA, Umar MF, Navarro-Martinez D et al.. “Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.” Vascular diseases (Paris, France) (2026). PMID: 41763910 ↗
L5SR_OBSCited in: Definition, Classification and Nomenclature
[32]
Tang L, He Y, Qiao Z et al.. “Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.” Frontiers in immunology (2026). PMID: 42344901 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[33]
Mahmoodi BK, Cushman M, Anne Næss I et al.. “Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective Studies.” Circulation (2016). PMID: 27831499 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications
[34]
Purnell JQ, Zinman B, Brunzell JD. “The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.” Circulation (2012). PMID: 23212717 ↗
L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[35]
Xie X, Shi X, Zhang Y et al.. “Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.” Journal of the American College of Cardiology (2025). PMID: 40167414 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[36]
Haine A, Kavanagh S, Berger JS et al.. “Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.” Journal of the American College of Cardiology (2020). PMID: 32057375 ↗
L2RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History
[37]
Boccara F, Kumar PN, Caramelli B et al.. “Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.” Journal of the American College of Cardiology (2020). PMID: 32234462 ↗
L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[38]
Shaw AT, Bauer TM, de Marinis F et al.. “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.” The New England journal of medicine (2020). PMID: 33207094 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
[39]
Ridker PM, Danielson E, Fonseca FA et al.. “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.” The New England journal of medicine (2008). PMID: 18997196 ↗
L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History
[40]
Basaria S, Coviello AD, Travison TG et al.. “Adverse events associated with testosterone administration.” The New England journal of medicine (2010). PMID: 20592293 ↗
L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[41]
Hudes G, Carducci M, Tomczak P et al.. “Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.” The New England journal of medicine (2007). PMID: 17538086 ↗
L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
[42]
Rossebø AB, Pedersen TR, Boman K et al.. “Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.” The New England journal of medicine (2008). PMID: 18765433 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
[43]
Kashani A, Phillips CO, Foody JM et al.. “Risks associated with statin therapy: a systematic overview of randomized clinical trials.” Circulation (2006). PMID: 17159064 ↗
L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications
[44]
Hong KN, Fuster V, Rosenson RS et al.. “How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD.” Journal of the American College of Cardiology (2017). PMID: 29050566 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications
[45]
Miller JD, Aronis KN, Chrispin J et al.. “Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation.” Journal of the American College of Cardiology (2015). PMID: 26718677 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications
[46]
Chou R, Dana T, Blazina I et al.. “Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2016). PMID: 27838722 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
[47]
Machline-Carrion MJ, Soares RM, Damiani LP et al.. “Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial.” JAMA cardiology (2019). PMID: 30942842 ↗
L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[48]
Ikramuddin S, Korner J, Lee WJ et al.. “Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.” JAMA (2013). PMID: 23736733 ↗
L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[49]
Kempen JH, Altaweel MM, Holbrook JT et al.. “Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.” JAMA (2017). PMID: 28477440 ↗
L2RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
[50]
Birger M, Kaldjian AS, Roth GA et al.. “Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016.” Circulation (2021). PMID: 33926203 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[51]
Saha P, Potiny P, Rigdon J et al.. “Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease.” Circulation (2019). PMID: 30813762 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[52]
DeCarlo C, Latz CA, Boitano LT et al.. “Prognostication of Asymptomatic Penetrating Aortic Ulcers: A Modern Approach.” Circulation (2021). PMID: 34376058 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, History and Evolution of Treatment, Complications, Prognosis and Natural History
[53]
Caleyachetty R, Thomas GN, Toulis KA et al.. “Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women.” Journal of the American College of Cardiology (2017). PMID: 28911506 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications
[54]
Lee HH, Crawford EB, Cho SMJ et al.. “Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.” Journal of the American College of Cardiology (2025). PMID: 41295934 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy
[55]
Sinha A, Ning H, Carnethon MR et al.. “Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure: A Population-Based Cohort Study From the Lifetime Risk Pooling Project.” Circulation. Heart failure (2021). PMID: 33761754 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification
[56]
Markus MRP, Ittermann T, Mariño Coronado J et al.. “Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.” European heart journal (2025). PMID: 40320753 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Complications
[57]
Wu J, Zafar MA, Liu Y et al.. “Fate of the unoperated ascending thoracic aortic aneurysm: three-decade experience from the Aortic Institute at Yale University.” European heart journal (2023). PMID: 36994934 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
[58]
Rafiee M, Mehmandoost S, Harandi F et al.. “Prevalence of Hypertension, Diabetes, Obesity, and High Cholesterol Among Older People Living With HIV: A Systematic Review and Meta-Analysis.” AIDS research and treatment (2026). PMID: 42358331 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors
[59]
Magnussen C, Alegre-Diaz J, Al-Nasser LA et al.. “Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.” The New England journal of medicine (2025). PMID: 40162648 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Complications, Prognosis and Natural History
[60]
Wang N, Li M, Lu M et al.. “Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review.” Medicine (2026). PMID: 42332507 ↗
L5SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy
[61]
Sadeghi E, Kozlov M, Hasan N et al.. “Associations between psychiatric disorders and medication use, and retinal occlusion: a large-scale retrospective cohort study.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42371026 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History
[62]
Thangjui S, Knutsen K, Hollowell B et al.. “Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42370998 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
[63]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy
[64]
Liu M, Marinacci LX, Joynt Maddox KE et al.. “Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors.” JAMA cardiology (2025). PMID: 40163358 ↗
L2OTHERCited in: Epidemiology and Risk Factors
[65]
Oseran AS, Sun T, Wadhera RK. “Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status.” JAMA cardiology (2022). PMID: 35648424 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy
[66]
Tung EL, Wroblewski KE, Makelarski JA et al.. “Childhood Parental Incarceration and Adult-Onset Hypertension and Cardiovascular Risk.” JAMA cardiology (2023). PMID: 37647038 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History
[67]
Gong J, Vaduganathan M, Wadhera RK. “Chronic Kidney Disease Prevalence and Awareness Among US Adults.” JAMA cardiology (2026). PMID: 41205219 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Special Populations and Prevention
[68]
Brandt EJ, Chang T, Leung C et al.. “Food Insecurity Among Individuals With Cardiovascular Disease and Cardiometabolic Risk Factors Across Race and Ethnicity in 1999-2018.” JAMA cardiology (2022). PMID: 36170056 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Complications
[69]
Whelton SP, McEvoy JW, Shaw L et al.. “Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors.” JAMA cardiology (2020). PMID: 32936272 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification
[70]
Bansal N, Katz R, Robinson-Cohen C et al.. “Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies.” JAMA cardiology (2017). PMID: 28002548 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Special Populations and Prevention
[71]
Honigberg MC, Zekavat SM, Aragam K et al.. “Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.” JAMA (2019). PMID: 31738818 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
[72]
Aggarwal R, Yeh RW, Joynt Maddox KE et al.. “Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020.” JAMA (2023). PMID: 36871237 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment
[73]
Record NB, Onion DK, Prior RE et al.. “Community-wide cardiovascular disease prevention programs and health outcomes in a rural county, 1970-2010.” JAMA (2015). PMID: 25585326 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention
[74]
Gelfand JM, Neimann AL, Shin DB et al.. “Risk of myocardial infarction in patients with psoriasis.” JAMA (2006). PMID: 17032986 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Prognosis and Natural History
[75]
McTigue K, Larson JC, Valoski A et al.. “Mortality and cardiac and vascular outcomes in extremely obese women.” JAMA (2006). PMID: 16820550 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History
[76]
Qin H, Tromp J, Ter Maaten JM et al.. “Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women.” JACC. Heart failure (2024). PMID: 39708029 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment, Complications
[77]
Xu Y, Yang H, Xu Q et al.. “Distinct From the Adult Paradigm: Re-Evaluate the Pathophysiological and Therapeutic Framework in Children and Adolescent Hyperlipidaemia.” Current obesity reports (2026). PMID: 42287583 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
[78]
Wang S, Wang L, Shi D et al.. “Relationship between hyperlipidemia and lumbar disc degeneration in patients with low back pain: an observational retrospective study.” Frontiers in physiology (2026). PMID: 42318506 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History
[79]
Yang W, Hu W, Pan Y et al.. “Impact of preoperative dual antiplatelet therapy vs. aspirin monotherapy on perioperative outcomes in carotid endarterectomy patients: a retrospective cohort study.” International journal of clinical pharmacy (2026). PMID: 42171869 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Complications
[80]
Piña IL, Zheng Q, She L et al.. “Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).” Circulation (2018). PMID: 29459462 ↗
L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Prognosis and Natural History
[81]
Ghattas A, Griffiths HR, Devitt A et al.. “Monocytes in coronary artery disease and atherosclerosis: where are we now?” Journal of the American College of Cardiology (2013). PMID: 23973684 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
[82]
Bravata DM, Smith-Spangler C, Sundaram V et al.. “Using pedometers to increase physical activity and improve health: a systematic review.” JAMA (2007). PMID: 18029834 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Clinical Presentation
[83]
Lee JK, Grace KA, Taylor AJ. “Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.” JAMA (2006). PMID: 17101639 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
[84]
Gu H, Wen J, Liu Y et al.. “SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure.” Circulation (2026). PMID: 42170742 ↗
L5OTHERCited in: Pathophysiology and Mechanism
[85]
Drechsler M, Megens RT, van Zandvoort M et al.. “Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis.” Circulation (2010). PMID: 20956207 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Complications
[86]
Li X, Zhu M, Penfold ME et al.. “Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue.” Circulation (2013). PMID: 24374972 ↗
L5OTHERCited in: Pathophysiology and Mechanism
[87]
Koskinas KC, Feldman CL, Chatzizisis YS et al.. “Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study.” Circulation (2010). PMID: 20439786 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
[88]
Lerman JB, Joshi AA, Chaturvedi A et al.. “Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.” Circulation (2017). PMID: 28483812 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
[89]
Seehaus S, Shahzad K, Kashif M et al.. “Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.” Circulation (2009). PMID: 19687358 ↗
L5OTHERCited in: Pathophysiology and Mechanism
[90]
Xiao H, Lu M, Lin TY et al.. “Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility.” Circulation (2013). PMID: 23838163 ↗
L5OTHERCited in: Pathophysiology and Mechanism
[91]
Alvi RM, Neilan AM, Tariq N et al.. “Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.” Journal of the American College of Cardiology (2018). PMID: 30049313 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Prognosis and Natural History
[92]
Jaguan D, Gratz BW, Jaguan SI et al.. “Treatment of Generalized Granuloma Annulare with JAK Inhibitors: Systematic Review.” Clinical, cosmetic and investigational dermatology (2026). PMID: 42111237 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Complications
[93]
Oshitari T. “Pathogenesis of Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with COVID-19.” International journal of molecular sciences (2026). PMID: 41898506 ↗
L5CASE_REPORTCited in: Pathophysiology and Mechanism
[94]
King WC, Hinerman AS, Belle SH et al.. “Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes.” JAMA (2018). PMID: 30326125 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[95]
Wijeysundera HC, Machado M, Farahati F et al.. “Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005.” JAMA (2010). PMID: 20460623 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management
[96]
Hall JE, Omoto ACM, do Carmo JM et al.. “Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.” Clinical science (London, England : 1979) (2026). PMID: 42340064 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications
[97]
Foroohar T, Berk-Krauss J, Caplan AS et al.. “Granuloma Annulare: An Updated Review of Epidemiology, Molecular Pathogenesis, and Management.” Journal of the American Academy of Dermatology (2026). PMID: 42320859 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy
[98]
Subauste CS. “Advances in the Role of the CD40-CD154 Pathway in the Pathogenesis of Diabetic Retinopathy.” International journal of molecular sciences (2026). PMID: 42123447 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[99]
Jovanovic K, Jovandaric MZ, Jovanovic D et al.. “Altered Lipid Profile and Oxidative Stress During Pregnancy: Impact on the Fetus and Risk of Metabolic Disorders in Adulthood.” International journal of molecular sciences (2026). PMID: 42123329 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Special Populations and Prevention
[100]
Lin L, Zi S, Zhang G et al.. “Advances in the pathogenesis of MASLD and its association with neutrophils.” Frontiers in medicine (2026). PMID: 41889493 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[101]
Kaplan R, Berni M, Caliogna L et al.. “Pathogenesis of Shoulder Calcific Tendinopathy.” International journal of molecular sciences (2026). PMID: 41828406 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[102]
Zhang M, Liu WL, Xu G et al.. “Hyperlipidemia in membranous nephropathy.” Clinical kidney journal (2026). PMID: 41822057 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[103]
Hsu JJ, Li Q, Tintut Y et al.. “Considerations in the Use of Mouse Models of Vascular and Valvular Calcification.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41739911 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[104]
Navar-Boggan AM, Peterson ED, D'Agostino RB et al.. “Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease.” Circulation (2015). PMID: 25623155 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
[105]
Pande RL, Perlstein TS, Beckman JA et al.. “Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004.” Circulation (2008). PMID: 18559705 ↗
L4OTHERCited in: Clinical Presentation
[106]
Fracassi F, Crea F, Sugiyama T et al.. “Healed Culprit Plaques in Patients With Acute Coronary Syndromes.” Journal of the American College of Cardiology (2019). PMID: 31072568 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
[107]
Kanner AM, Bicchi MM. “Antiseizure Medications for Adults With Epilepsy: A Review.” JAMA (2022). PMID: 35380580 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[108]
Choi SI, Heo Y, Ryu SW et al.. “Safety, Efficacy, and Quality of Life Outcomes of Bariatric and Metabolic Surgery in Korea: A Prospective Multicenter Cohort Study.” Obesity surgery (2026). PMID: 42098468 ↗
L2COHORTCited in: Clinical Presentation
[109]
Lu Z, Zong D, Yang Z et al.. “Risk factors for rebleeding in acute lower gastrointestinal bleeding: a systematic review and meta-analysis.” International journal of colorectal disease (2026). PMID: 42287444 ↗
L1SR_OBSCited in: Clinical Presentation, Acute and Initial Management
[110]
Tu Y, Sun Y, Zhu M et al.. “Bilateral extensive adult-onset limbal xanthogranuloma invading the deep corneal stroma: a case report and literature review.” Frontiers in medicine (2026). PMID: 42369137 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment
[111]
Laffin LJ, Bruemmer D, Garcia M et al.. “Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.” Journal of the American College of Cardiology (2022). PMID: 36351465 ↗
L1RCTCited in: Diagnosis and Workup, History and Evolution of Treatment, Complications
[112]
Miller JD, Weiss RM, Serrano KM et al.. “Lowering plasma cholesterol levels halts progression of aortic valve disease in mice.” Circulation (2009). PMID: 19433756 ↗
L5OTHERCited in: Diagnosis and Workup, Complications
[113]
Roifman I, Therrien J, Ionescu-Ittu R et al.. “Coarctation of the aorta and coronary artery disease: fact or fiction?” Circulation (2012). PMID: 22675158 ↗
L2OTHERCited in: Diagnosis and Workup
[114]
Masri A, Kalahasti V, Svensson LG et al.. “Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With a Trileaflet Aortic Valve and a Dilated Aorta.” Circulation (2016). PMID: 27770001 ↗
L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
[115]
Miller TD, Redberg RF, Wackers FJ. “Screening asymptomatic diabetic patients for coronary artery disease: why not?” Journal of the American College of Cardiology (2006). PMID: 16904546 ↗
L5OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
[116]
Cavusoglu E, Kornecki E, Sobocka MB et al.. “Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis.” Journal of the American College of Cardiology (2007). PMID: 17964041 ↗
L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
[117]
Civeira F, Jarauta E, Cenarro A et al.. “Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.” Journal of the American College of Cardiology (2008). PMID: 19007590 ↗
L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
[118]
Zeng Y, Sun Y. “Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators.” BMC women's health (2026). PMID: 41952141 ↗
L2COHORTCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
[119]
Chiang LH, Tsai PH, Chen YF et al.. “Real-World Safety and Retention of Tofacitinib in Elderly Versus Non-elderly Patients With Rheumatoid Arthritis: A Retrospective Cohort Study in Taiwan.” International journal of rheumatic diseases (2026). PMID: 42177625 ↗
L2COHORTCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
[120]
Zhou X, Yang C, Zou T et al.. “Shared Genetic Risk Between Acute Pancreatitis and Metabolic Syndrome Converges on a BCAT1-Positive Fibroblast Subpopulation and MAPK14-Driven Inflammation.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 42402174 ↗
L2OTHERCited in: Diagnosis and Workup, Acute and Initial Management
[121]
Qin Y, Hong Y, Ning L et al.. “Subtype-Specific Associations Between Hyperlipidemia and Age-Related Cataract: A Clinic-Based Cross-Sectional Study.” Clinical interventions in aging (2026). PMID: 42333214 ↗
L4OTHERCited in: Diagnosis and Workup
[122]
Li S, Wen ZQ, Yan P. “Zexie decoction alleviates hyperlipidemia through modulation of the PPAR signaling pathway and lysophospholipid metabolism.” Pharmaceutical biology (2026). PMID: 42295113 ↗
L5OTHERCited in: Diagnosis and Workup
[123]
Huang X, Lu N, Yu H et al.. “The impact of 1-hour plasma glucose on the metabolic characteristics and pregnancy outcomes in polycystic ovary syndrome.” Nutrition & diabetes (2026). PMID: 42285965 ↗
L2OTHERCited in: Diagnosis and Workup
[124]
Yin WL, Peng L, Zhang JH et al.. “Hyperlipid-Related Alzheimer's Disease: Potential Role of CircUCK2/miR-24-3p/p38 Axis in Neuronal Damage.” Comprehensive Physiology (2026). PMID: 42281258 ↗
L3OTHERCited in: Diagnosis and Workup
[125]
Nagaoka M, Nagaoka K, Kajitani N et al.. “Serum Mac-2 Binding Protein Glycan Isomer and Cerebral White Matter Injury in Older Adults: A Hepatic-Cerebral Link.” Hepatology research : the official journal of the Japan Society of Hepatology (2026). PMID: 42246447 ↗
L4OTHERCited in: Diagnosis and Workup
[126]
Zhong XY, Peng R, Deng Y et al.. “Drinking Patterns and CT/MRI Feature-Based Nomogram Models Can More Accurately Predict Acute Alcoholic Pancreatitis Recurrence.” Alcohol, clinical & experimental research (2026). PMID: 42246257 ↗
L3OTHERCited in: Diagnosis and Workup
[127]
Li W, Fredriksson M, Dernroth DN et al.. “Sex differences in iron stores and associations of body iron with cardiovascular risk factors in the middle-aged general population.” Frontiers in endocrinology (2026). PMID: 42222086 ↗
L4OTHERCited in: Diagnosis and Workup
[128]
Ata HS, Abd El-Rady NM, Gomaa AMS et al.. “Neurodegenerative and Glial Physiology in Diabetic Retinopathy: Dissociated Effects of Forskolin on Neuronal Survival and Glial Activation.” Biomedicines (2026). PMID: 42193428 ↗
L5OTHERCited in: Diagnosis and Workup
[129]
Ridker PM, MacFadyen J, Cressman M et al.. “Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.” Journal of the American College of Cardiology (2010). PMID: 20206456 ↗
L1TRIAL_NONRANDOMCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
[130]
Zhang D, Jiang X, Fang P et al.. “Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice.” Circulation (2009). PMID: 19858416 ↗
L5OTHERCited in: Severity Staging and Risk Stratification
[131]
Fu J, Zhou Y, Zhang F et al.. “Risk factors for postoperative venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 41613334 ↗
L2SR_OBSCited in: Severity Staging and Risk Stratification
[132]
Wu HL, Chen JT, Cata JP et al.. “Preoperative proprotein convertase subtilisin/kexin type 9 inhibitors versus statins and postoperative adverse events in hyperlipidemia: A nationwide, active-comparator cohort study.” Atherosclerosis (2026). PMID: 42048760 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, Prognosis and Natural History
[133]
Wolff K, Gumin D, Shqara RA et al.. “Risk factors and predictive modeling for occult endometrial cancer in women with atypical hyperplasia: a retrospective study.” Archives of gynecology and obstetrics (2026). PMID: 41611996 ↗
L3COHORTCited in: Severity Staging and Risk Stratification
[134]
Zhong W, Jiang F, Wang H et al.. “Polypharmacy, determinants, and adverse outcomes in elderly patients with heart failure: a multicenter retrospective cohort study of 7,361 subjects.” BMC geriatrics (2026). PMID: 41588351 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
[135]
Li J, Wang Y, Chen Z et al.. “Association between autologous blood transfusion and serum creatinine in patients with acute Stanford-A aortic dissection based on a retrospective study.” BMC anesthesiology (2026). PMID: 41566236 ↗
L3COHORTCited in: Severity Staging and Risk Stratification
[136]
Zhang Y, Zhang X, Song H et al.. “Predicting short-term composite outcome risk in heart failure patients using a machine learning model incorporating UHR: a retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42305866 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment
[137]
Shen Q, Zhou S, Ouyang X et al.. “Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: a real-world cohort study.” Heart & lung : the journal of critical care (2026). PMID: 42030746 ↗
L2COHORTCited in: Severity Staging and Risk Stratification
[138]
Cheng ZT, Wang JL, Zhao YB et al.. “Association Between the Lactate-to-Albumin Ratio and ICU/In-Hospital Mortality in Critically Ill Patients With Comorbid Type 2 Diabetes Mellitus : A Cohort Study Utilizing the MIMIC-IV Database.” Emergency medicine international (2026). PMID: 41982276 ↗
L2COHORTCited in: Severity Staging and Risk Stratification
[139]
Vega RB, O'Mahony G, Barbour AM et al.. “Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.” Circulation (2026). PMID: 42137960 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[140]
Ballantyne CM, Gaudet D, Rosenson RS et al.. “Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.” Journal of the American College of Cardiology (2025). PMID: 40099777 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[141]
McKenney JM, Farnier M, Lo KW et al.. “Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.” Journal of the American College of Cardiology (2006). PMID: 16630994 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[142]
Rosenson RS, Gaudet D, Hegele RA et al.. “Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38809174 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[143]
Blom DJ, Hala T, Bolognese M et al.. “A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.” The New England journal of medicine (2014). PMID: 24678979 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[144]
Ballantyne CM, Vasas S, Azizad M et al.. “Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38804517 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[145]
Ridker PM, Tardif JC, Amarenco P et al.. “Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.” The New England journal of medicine (2017). PMID: 28304227 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[146]
Puzziferri N, Roshek TB, Mayo HG et al.. “Long-term follow-up after bariatric surgery: a systematic review.” JAMA (2014). PMID: 25182102 ↗
L2SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
[147]
Berthold HK, Unverdorben S, Degenhardt R et al.. “Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.” JAMA (2006). PMID: 16705107 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
[148]
Smilowitz NR, Mega JL, Berger JS. “Duration of anticoagulation for venous thromboembolic events.” Circulation (2014). PMID: 25539522 ↗
L4CASE_REPORTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
[149]
Schwab RD, Degaramo D, Hong SJ et al.. “Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development.” Circulation (2025). PMID: 41268661 ↗
L5OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
[150]
Al Mheid I, Quyyumi AA. “Vitamin D and Cardiovascular Disease: Controversy Unresolved.” Journal of the American College of Cardiology (2017). PMID: 28662812 ↗
L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[151]
Moccetti F, Brown E, Xie A et al.. “Myocardial Infarction Produces Sustained Proinflammatory Endothelial Activation in Remote Arteries.” Journal of the American College of Cardiology (2018). PMID: 30139430 ↗
L5OTHERCited in: Acute and Initial Management
[152]
Hsu J, Price M, Huang J et al.. “Unintended consequences of caps on Medicare drug benefits.” The New England journal of medicine (2006). PMID: 16738271 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
[153]
Jackevicius CA, Tu JV, Ross JS et al.. “Use of ezetimibe in the United States and Canada.” The New England journal of medicine (2008). PMID: 18375999 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
[154]
Meng X, Ou Y, Mao J et al.. “LDAR outperforms other albumin-derived indices in predicting 28-day ICU mortality in critically ill myocardial infarction patients: a two-cohort study.” Frontiers in medicine (2026). PMID: 42221102 ↗
L2COHORTCited in: Acute and Initial Management
[155]
Whitmer RA, Karter AJ, Yaffe K et al.. “Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.” JAMA (2009). PMID: 19366776 ↗
L2OTHERCited in: Acute and Initial Management
[156]
Choi H, Choi J, Maksatbekov C et al.. “Predictors of in-hospital case-fatality in patients with stroke at the National Hospital of the Kyrgyz Republic: a retrospective cohort study.” BMC neurology (2026). PMID: 42216139 ↗
L2COHORTCited in: Acute and Initial Management
[157]
Devanita S LA, Adhyatma IGR, Cahya KKD. “Risk factors of cerebral vasospasm associated with ruptured arterio-venous malformation: A systematic review and meta-analysis.” Journal of cerebrovascular and endovascular neurosurgery (2026). PMID: 42374993 ↗
L2SR_OBSCited in: Acute and Initial Management
[158]
Liao HW, Luyckx V, Ostermann M et al.. “Severe Pregnancy-Associated Acute Kidney Injury and Maternal Vulnerability.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 42406539 ↗
L2OTHERCited in: Acute and Initial Management
[159]
Jiang Q, Wang R, He Y et al.. “Construction and Validation of a 90-Day Mortality Risk Prediction Model Based on Interpretable Machine Learning for Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy.” Journal of clinical medicine (2026). PMID: 42355869 ↗
L2OTHERCited in: Acute and Initial Management
[160]
Foody JM, Shah R, Galusha D et al.. “Statins and mortality among elderly patients hospitalized with heart failure.” Circulation (2006). PMID: 16490817 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention
[161]
Bair TL, Muhlestein JB, May HT et al.. “Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry.” Circulation (2007). PMID: 17846308 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
[162]
Piazza G, Campia U, Hurwitz S et al.. “Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.” Journal of the American College of Cardiology (2020). PMID: 33121712 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History
[163]
Allard NAE, Janssen L, Aussieker T et al.. “Moderate Intensity Exercise Training Improves Skeletal Muscle Performance in Symptomatic and Asymptomatic Statin Users.” Journal of the American College of Cardiology (2021). PMID: 34794683 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy
[164]
Mancini GBJ, Lincoff AM, Goldberg AC et al.. “Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.” Journal of the American Heart Association (2026). PMID: 42333640 ↗
L1RCTCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention
[165]
Reges O, Greenland P, Dicker D et al.. “Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality.” JAMA (2018). PMID: 29340677 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy
[166]
Wu J, Zhang F, Li Q et al.. “Predictors of difficult vascular access during transradial neurointervention: a retrospective study.” Revista da Associacao Medica Brasileira (1992) (2026). PMID: 42339907 ↗
L2COHORTCited in: Long-term Guideline-Directed Therapy
[167]
Duan Y, Pan Z, Gu J et al.. “Disparities in anticoagulation therapy for older adults with non-valvular atrial fibrillation: a comparative study of urban and suburban communities.” BMC geriatrics (2026). PMID: 42420880 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy
[168]
Papatheodoridis G, Buti M, Yilmaz Y et al.. “Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes.” Journal of gastroenterology and hepatology (2026). PMID: 42419754 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy
[169]
Yu M, Lei C, Zou T et al.. “Multidimensional factors influencing the recovery trajectory of residual dizziness after successful canalith repositioning in benign paroxysmal positional vertigo: an ordered logistic regression analysis.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026). PMID: 42402503 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy
[170]
Jafari EA. “Hypertension among Middle Eastern and North African adults residing in the United States: addressing equity in health research representation using the All of Us Research Program, 2000-2024.” Frontiers in medicine (2026). PMID: 42383063 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy
[171]
Dabour MS, Shaaban A, Duprez DA et al.. “Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?” Breast cancer research and treatment (2026). PMID: 42329476 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy
[172]
Peng L, Zhu N, Zhang CJ et al.. “Beyond lipid-lowering effects: Challenges and insights in fenofibrate repurposing for oncology.” Life sciences (2026). PMID: 42302925 ↗
L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy
[173]
Han X, Hopkins SC, Zhang Z et al.. “The Economic Impact of Cumulative Metabolic Comorbidity Burden in Schizophrenia: A Claims-Based Analysis of Medical Costs in the United States.” Neurology and therapy (2026). PMID: 42301550 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy
[174]
Zhang X, Xu H, Yu J et al.. “Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection.” Circulation (2023). PMID: 37232170 ↗
L5OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History
[175]
Kim YH, Park DW, Lee SW et al.. “Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.” Circulation (2009). PMID: 19620506 ↗
L2OTHERCited in: Interventional and Device Therapy, Special Populations and Prevention
[176]
Koupenova M, Johnston-Cox H, Vezeridis A et al.. “A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.” Circulation (2011). PMID: 22144568 ↗
L5OTHERCited in: Interventional and Device Therapy
[177]
Thomas M, Schymik G, Walther T et al.. “One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.” Circulation (2011). PMID: 21747054 ↗
L4OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History
[178]
Yu E, Calvert PA, Mercer JR et al.. “Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans.” Circulation (2013). PMID: 23841983 ↗
L4OTHERCited in: Interventional and Device Therapy
[179]
Molony DS, Hung O, Corban M et al.. “A randomized prospective study investigating the relationship between post-PCI wall shear stress and 12-month neointimal healing: The SHEAR-STENT study.” Cardiovascular revascularization medicine : including molecular interventions (2025). PMID: 41285658 ↗
L1RCTCited in: Interventional and Device Therapy
[180]
Önder R, Geebelen G, Scherrenberg M et al.. “The impact of cardiac rehabilitation on atrial fibrillation recurrence after pulmonary vein isolation: results of a large retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 41674867 ↗
L2COHORTCited in: Interventional and Device Therapy
[181]
Zhu Q, Zhang Y, Liu J et al.. “Clinical validation study of a novel prognostic risk prediction model (CHIP Score) for interventional therapy in patients with NSTE-ACS-a single-center retrospective cohort study based on 348 patients.” BMC cardiovascular disorders (2026). PMID: 41507846 ↗
L2COHORTCited in: Interventional and Device Therapy
[182]
Li W, Zhang G, Chen Y et al.. “Incidence and risk factors of posttransplant diabetes mellitus in lung transplant recipients: a retrospective cohort study.” Journal of thoracic disease (2025). PMID: 41376958 ↗
L2COHORTCited in: Interventional and Device Therapy
[183]
Lin X, Wang Y, Tan S et al.. “Long-term safety, effectiveness, and cost of rapamycin- vs. everolimus-eluting stents in acute coronary syndrome: a real-world cohort study.” International journal of clinical pharmacy (2025). PMID: 41369785 ↗
L2COHORTCited in: Interventional and Device Therapy
[184]
Yen WC, Yang MH, Weng TH et al.. “Dialysis and the risk of early urological cancer: A nationwide population-based cohort study in Taiwan.” Medicine (2025). PMID: 40388720 ↗
L2COHORTCited in: Interventional and Device Therapy
[185]
Wu P, Kiram A, Zhu Y et al.. “Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis.” Metabolism: clinical and experimental (2026). PMID: 42225205 ↗
L5OTHERCited in: Interventional and Device Therapy
[186]
Wang X, Song Y, Zhao W et al.. “Cinnamaldehyde mitigates MASLD through SIRT1/FOXO1-induced autophagy and synergistic gut microbiota modulation.” NPJ science of food (2026). PMID: 41957048 ↗
L5OTHERCited in: Interventional and Device Therapy
[187]
Williams ZE, Singh I, Marks N et al.. “Innovative wound management of refractory venous ulcers with topical oxygen therapy.” Journal of vascular surgery. Venous and lymphatic disorders (2026). PMID: 41864536 ↗
L4OTHERCited in: Interventional and Device Therapy
[188]
Zhang Y, Teng M, He W et al.. “4-Hydroxybenzyl Alcohol Mitigates Hyperlipidemia-Associated Depression by Inhibiting Neuroinflammation via the NKIRAS2/NF-κB Pathway.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41801218 ↗
L5OTHERCited in: Interventional and Device Therapy
[189]
Torosian K, Díaz LA, Tesfai K et al.. “Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-associated Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41679525 ↗
L2OTHERCited in: Interventional and Device Therapy
[190]
Ding M, Xiao Z, Hou X et al.. “Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease.” Chinese medicine (2026). PMID: 41580820 ↗
L5OTHERCited in: Interventional and Device Therapy
[191]
Ambardekar AV, Bhatt A, Hoekstra M et al.. “Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.” Journal of the American College of Cardiology (2026). PMID: 41885675 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[192]
März W, Scharnagl H, Abletshauser C et al.. “Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.” Circulation (2001). PMID: 11306521 ↗
L1RCTCited in: History and Evolution of Treatment
[193]
Lansky AJ, Pietras C, Costa RA et al.. “Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Circulation (2005). PMID: 15811868 ↗
L1RCTCited in: History and Evolution of Treatment
[194]
Vaduganathan M, Bhatt DL, Cryer BL et al.. “Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.” Journal of the American College of Cardiology (2016). PMID: 27012778 ↗
L1RCTCited in: History and Evolution of Treatment, Complications
[195]
Guyton JR, Brown BG, Fazio S et al.. “Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.” Journal of the American College of Cardiology (2008). PMID: 18420099 ↗
L1RCTCited in: History and Evolution of Treatment
[196]
Nappo F, Esposito K, Cioffi M et al.. “Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.” Journal of the American College of Cardiology (2002). PMID: 11923038 ↗
L1RCTCited in: History and Evolution of Treatment
[197]
Naoumova RP, Kindler H, Leccisotti L et al.. “Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.” Journal of the American College of Cardiology (2007). PMID: 18021872 ↗
L1RCTCited in: History and Evolution of Treatment
[198]
Herrington DM, Werbel BL, Riley WA et al.. “Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.” Journal of the American College of Cardiology (1999). PMID: 10362210 ↗
L1RCTCited in: History and Evolution of Treatment
[199]
Blake GJ, Albert MA, Rifai N et al.. “Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial.” European heart journal (2003). PMID: 14563343 ↗
L1RCTCited in: History and Evolution of Treatment
[200]
Austin MA, McKnight B, Edwards KL et al.. “Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study.” Circulation (2000). PMID: 10859281 ↗
L2COHORTCited in: History and Evolution of Treatment
[201]
Jenkins DJ, Wolever TM, Rao AV et al.. “Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol.” The New England journal of medicine (1993). PMID: 8389421 ↗
L1RCTCited in: History and Evolution of Treatment
[202]
Ridker PM, Rifai N, Clearfield M et al.. “Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.” The New England journal of medicine (2001). PMID: 11430324 ↗
L1RCTCited in: History and Evolution of Treatment
[203]
Walsh JM, Pignone M. “Drug treatment of hyperlipidemia in women.” JAMA (2004). PMID: 15138247 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[204]
Szapary PO, Wolfe ML, Bloedon LT et al.. “Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.” JAMA (2003). PMID: 12915429 ↗
L1RCTCited in: History and Evolution of Treatment
[205]
Esposito K, Giugliano F, Di Palo C et al.. “Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial.” JAMA (2004). PMID: 15213209 ↗
L1RCTCited in: History and Evolution of Treatment
[206]
Ballantyne CM, Podet EJ, Patsch WP et al.. “Effects of cyclosporine therapy on plasma lipoprotein levels.” JAMA (1989). PMID: 2733125 ↗
L2RCTCited in: History and Evolution of Treatment
[207]
Esposito K, Pontillo A, Di Palo C et al.. “Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.” JAMA (2003). PMID: 12684358 ↗
L1RCTCited in: History and Evolution of Treatment
[208]
Jenkins DJ, Jones PJ, Lamarche B et al.. “Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.” JAMA (2011). PMID: 21862744 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History
[209]
Brass EP. “Changing the status of drugs from prescription to over-the-counter availability.” The New England journal of medicine (2001). PMID: 11556302 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[210]
Ridker PM, Hennekens CH, Rifai N et al.. “Hormone replacement therapy and increased plasma concentration of C-reactive protein.” Circulation (1999). PMID: 10449692 ↗
L4OTHERCited in: History and Evolution of Treatment
[211]
Beaumont V, Lemort N, Beaumont JL. “Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases.” European heart journal (1991). PMID: 1782953 ↗
L3OTHERCited in: History and Evolution of Treatment
[212]
Ahmad A, Khan M, Ghayyad K et al.. “Statin therapy is not associated with inferior postoperative outcomes after arthroscopic rotator cuff repair: a systematic review and meta-analysis.” Journal of shoulder and elbow surgery (2026). PMID: 42173477 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prognosis and Natural History
[213]
Jia D, Wang H, Jiang W et al.. “A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.” Frontiers in immunology (2026). PMID: 42079612 ↗
L1RCTCited in: History and Evolution of Treatment, Complications
[214]
Song X, Hu Y, Chen Y. “Uterine fibroids detected in early pregnancy and their association with adverse pregnancy outcomes: a single-centre retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42026504 ↗
L4COHORTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
[215]
Fancher A, Lopez-Candales A, Sawalha K. “Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management.” Journal of lipid and atherosclerosis (2025). PMID: 42211141 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[216]
Wang L, Niu Y, Wang L. “Pontine infarction isolated to trigeminal sensory fibers: a case report.” Frontiers in pain research (Lausanne, Switzerland) (2026). PMID: 42317569 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[217]
Arias-Romero J, Mambetsariev I, Fricke J et al.. “Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.” Translational lung cancer research (2026). PMID: 42291351 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[218]
Bauer RC, Tohyama J, Cui J et al.. “Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.” Circulation (2015). PMID: 25712206 ↗
L5OTHERCited in: Complications
[219]
Coberly EA, Hammer RD. “Images in clinical medicine: Morphologic changes in erythrocytes in hypertriglyceridemia.” The New England journal of medicine (2014). PMID: 25119625 ↗
L4CASE_REPORTCited in: Complications
[220]
Zhang J, Hu Z, Song C et al.. “Hemoglobin glycation index correlates with the prognoses of critically ill patients with hyperlipidemia: a retrospective cohort study from the MIMIC-IV database.” BMC endocrine disorders (2026). PMID: 42168947 ↗
L4COHORTCited in: Complications, Prognosis and Natural History
[221]
Zulfa IM, Risni HW, Brauer R et al.. “Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.” Postgraduate medicine (2026). PMID: 42357832 ↗
L1SR_OBSCited in: Complications
[222]
Zeng C, Lyu H, Lou L et al.. “Association between stress hyperglycemic ratio and stroke in older people with metabolic syndrome: a prospective cohort study from UK Biobank.” Frontiers in endocrinology (2026). PMID: 42051452 ↗
L2COHORTCited in: Prognosis and Natural History
[223]
Lee YJ, Lee JH, Kim M et al.. “Combined Pre-Hypertension, Pre-Diabetes, and Pre-Hyperlipidemia and Long-Term Cardiovascular Risk in Young Adults: A Nationwide Cohort Study.” European journal of preventive cardiology (2026). PMID: 42044147 ↗
L2COHORTCited in: Prognosis and Natural History
[224]
Nourollahpour Shiadeh M, Pakdaman K, Esmaeilnia Shirvani A et al.. “Global incidence and risk factors of pregnancy-related stroke: a systematic review and meta-analysis of over 270 million women.” BMC pregnancy and childbirth (2025). PMID: 41419807 ↗
L1SR_OBSCited in: Special Populations and Prevention
[225]
Yan C, Shen X, Han S et al.. “Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study.” Journal of translational medicine (2026). PMID: 41782035 ↗
L2COHORTCited in: Special Populations and Prevention
[226]
Camara J, Tsujiguchi H, Hara A et al.. “Chronic pain and mortality risk among middle-age and older Japanese: the Shika town cohort study.” Pain reports (2025). PMID: 41244944 ↗
L2COHORTCited in: Special Populations and Prevention
[227]
Chen Y, Huang L, Hu T et al.. “The changing trend of hepatitis B virus carrier rate with different combinations of hepatitis B virus markers and their impact on maternal perinatal characteristics and pregnancy outcomes: a multicenter retrospective cohort study.” Virology journal (2025). PMID: 41214772 ↗
L3COHORTCited in: Special Populations and Prevention
[228]
Naim MAAZ, Sumida K, Streja E et al.. “Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol.” Drugs (2026). PMID: 41528633 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention
[229]
Hsiao PJ, Tsou LL, Yang CC et al.. “Magnesium Oxide Use and Clinical Outcomes in CKD Patients: Evidence from a Nationwide Population-Based Cohort Study in Taiwan.” International journal of medical sciences (2026). PMID: 41938509 ↗
L3COHORTCited in: Special Populations and Prevention
[230]
Delbari A, Akbarzadeh I, Bidkhori M et al.. “The Prevalence and Associated Factors of Smoking and Smoking-Cessation in Iranian Older Adults: Ardakan Cohort Study on Aging (ACSA).” Substance use & misuse (2026). PMID: 41782359 ↗
L4COHORTCited in: Special Populations and Prevention
[231]
You X, Xu Y, Zhao J et al.. “The association of geriatric nutritional risk and perioperative anesthesia-related adverse reactions in elderly patients with colorectal cancer-a prospective study.” Translational cancer research (2025). PMID: 41234882 ↗
L2COHORTCited in: Special Populations and Prevention

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification and Nomenclature

Synonyms and Abbreviations

Classification Axes

Key Terms Used Throughout This Article

Clinical Significance

Epidemiology and Risk Factors

Demographic and Geographic Variation

Temporal Trends

Risk Factor Profile

Risk Factors for Hyperlipidemia

Pathophysiology and Mechanism

Lipoprotein Retention and Oxidative Modification

Endothelial Activation and Leukocyte Recruitment

Foam Cell Formation and Plaque Progression

Role of Inflammation and Plaque Vulnerability

Key Mediators of Hyperlipidemia-Driven Atherogenesis

Clinical Presentation

Presenting Symptoms

Physical Examination Findings

Phenotypic Variants

Red Flags Requiring Urgent Action

Atypical Presentations

Diagnosis and Workup

History and Physical

Laboratory Studies (Gold-Standard Test)

Genetic Testing

Diagnostic Algorithm

Differential Diagnosis

Severity Staging and Risk Stratification

Global Cardiovascular Risk Assessment

Severe Hyperlipidemia and Genetic Syndromes

Emerging Risk Stratification Tools

Acute and Initial Management

Step 1: Identify Urgency

Step 2: First-Line Pharmacotherapy

Step 3: Initiate and Titrate

Step 4: Monitoring and Transition

Controversies and Guideline Disagreement

Long-term Guideline-Directed Therapy

Step 1: Initiate and maximize statin therapy

Step 2: Add ezetimibe when LDL-C remains above goal

Step 3: Add PCSK9 inhibitor or bempedoic acid for very high risk or statin intolerance

Step 4: Manage hypertriglyceridemia

Step 5: Monitor adherence and adjust every 3-12 months

What NOT to do

Controversies and Guideline Disagreement

Interventional and Device Therapy

Lipoprotein Apheresis

Revascularization in Hyperlipidemic Patients

Comparative Outcomes of Revascularization Strategies

History and Evolution of Treatment

Statin Monotherapy: The Foundational Era

The Combination Therapy Era and Abandoned Approaches

The PCSK9 Revolution: Monoclonal Antibodies, siRNA, and the First Oral Agent

Beyond LDL-C: ANGPTL3, APOC3, and Lp(a) Targets

The Gene Editing Horizon

Complications

Disease-Related Complications

Therapy-Related Complications

Prognosis and Natural History

Special Populations and Prevention

Pregnancy

Chronic Kidney Disease

Elderly

Prevention Across Populations

References

Global

Step 2: Add when LDL-C remains above goal

Step 4: Manage